



## Review article

## Challenges and strategies for the delivery of biologics to the cornea

M. Wels<sup>a</sup>, D. Roels<sup>b</sup>, K. Raemdonck<sup>a</sup>, S.C. De Smedt<sup>a,c</sup>, F. Sauvage<sup>a,\*</sup><sup>a</sup> Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, 9000 Ghent, Belgium<sup>b</sup> Department of Ophthalmology, Ghent University Hospital, Corneel Heymanslaan 10, 9000 Ghent, Belgium<sup>c</sup> Joint Laboratory of Advanced Biomedical Materials (NFU-UGent), College of Chemical Engineering, Nanjing Forestry University (NFU), Nanjing 210037, PR China

## ARTICLE INFO

## Keywords:

Cornea  
 Delivery barriers  
 Transfection  
 Gene gun  
 Viral vectors  
 Microneedles  
 Nanomedicine  
 Corneal diseases

## ABSTRACT

Biologics, like peptides, proteins and nucleic acids, have proven to be promising drugs for the treatment of numerous diseases. However, besides the off label use of the monoclonal antibody bevacizumab for the treatment of corneal neovascularization, to date no other biologics for corneal diseases have reached the market. Indeed, delivering biologics in the eye remains a challenge, especially at the level of the cornea. While it appears to be a rather accessible tissue for the administration of drugs, the cornea in fact presents several anatomical barriers to delivery. In addition, also intracellular delivery barriers need to be overcome to achieve a promising therapeutic outcome with biologics. This review outlines efforts that have been reported to successfully deliver biologics into the cornea. Biochemical and physical methods for achieving delivery of biologics in the cornea are discussed, with a critical view on their efficacy in overcoming corneal barriers.

## 1. Introduction

The cornea is a clear avascular tissue located at the anterior side of the eye. It is around 560  $\mu\text{m}$  thick and consists of different layers, each with its own structure and barriers (Fig. 1). The main role of the cornea is to refract, or bend, light in the direction of the lens and retina. Secondly, together with the neighboring sclera, it serves as an external barrier to protect the intraocular structures. Diseases at the level of the cornea can tremendously impact vision, which explains why corneal blindness is the fourth leading cause of blindness after cataract, glaucoma and age-related macular degeneration (AMD) [1]. This encompasses corneal visual impairment due to a wide variety of infectious and inflammatory diseases, mechanical injury, thermal and chemical burn, refractive errors as well as several corneal dystrophies. Quick and complete healing of the cornea is of utmost importance, however, in certain patients such as those suffering from neurotrophic keratopathy, the healing process is altered after damage resulting in persisting epithelial defects [2]. Also, the cornea of diabetic patients can exhibit a delayed wound-healing response leading to ocular surface irregularities or scarring, thus hindering clear vision [3].

Corneal blindness does not only impact normal daily life but also the mental condition of the patients. Studies have shown that only a third of the adults with a severe visual impairment report a good quality of life. Likewise, in children a moderate or severe impairment can significantly

influence their quality of life [4,5]. For many corneal diseases, no permanent therapeutic solutions are available and corneal transplantation is therefore often needed. Currently, there is a huge unmet medical need as less than 1.5% of the transplantation needs are covered worldwide [6], due to the scarcity of good quality grafts and difficult access in developing countries [7]. Clearly, alternatives are needed to combat the unnecessary blinding. For this matter, corneal bioengineering (i.e. 3D printed corneas [8] and scaffolds [9]) or genetic strategies are extensively being explored.

In the context of corneal diseases, biologics (i.e. nucleic acid and protein drugs) offer great promise as they specifically interfere with targets and pathways [10]. Especially for treating corneal disorders nucleic acid therapeutics are of interest as in many dystrophies, which are often hereditary, specific genes need to be addressed, e.g. Meesmann corneal dystrophy (KRT3 and 12 genes) [11], Fuchs endothelial dystrophy (COL8A2 gene) [11] and epithelial recurrent erosion dystrophy (COL17A1 gene) [12]. In the healing process, specific proteins are also involved (i.e. EGF, TGF- $\beta$  and TNF- $\alpha$  for epithelial healing [13] or MyoD, to recover stromal keratocyte transparency [14]) and their function can be modulated by administering biologics to the cornea.

## 2. The barriers of the cornea

Even though the cornea appears to be a readily available tissue for

\* Corresponding author at: Ottergemsesteenweg 460, 9000 Ghent, Belgium.  
 E-mail address: [Felix.Sauvage@ugent.be](mailto:Felix.Sauvage@ugent.be) (F. Sauvage).

drugs by its location at the surface of the eye, its structure made of several barriers makes efficient drug delivery of biologics highly challenging. As illustrated in Fig. 1B, therapeutics administered topically to the cornea have to overcome different static and dynamic barriers. The outermost barrier is the pre-corneal aqueous **tear film**. It serves as the primary refractive surface for light and also to moisturize and protect the cornea [15]. The tear film volume is around 7–10  $\mu\text{l}$ . The maximum volume of fluid the surface area of the eye can hold is 30  $\mu\text{l}$  due to the additional storage of the lacrimal sac. The average tear drop sizes still exceed this volume and lead to a spillover in the form of tears losing a portion of topically administered drug even before it is able to reach the ocular tissues [16]. The remainder will be diluted in the tear film, which is renewed with a turnover rate of  $16\% \text{ min}^{-1}$ . With the average tear film volume this converts to an average tear flow of 1.2  $\mu\text{l}/\text{min}$  [16]. This dilution shortens the contact time of topically administered drugs with the corneal surface, as they are quickly drained through the nasolacrimal duct where they are systemically absorbed [17,18]. As Fig. 1B shows, the tear film has an outer lipid layer that is important in tear stability [19]. In the aqueous section of the film, interaction of the drug with tear enzymes (such as lysozyme), mucins and proteins (such as albumin) can lead to non-specific binding. This binding makes drugs unable to reach their target and they are thus cleared rapidly [20,21]. Close to the epithelium a secreted gel, the **mucin layer**, can be found and acts as a barrier to pathogens [22–25]. This layer consists mostly of proteins such as MUC1, MUC4 and MUC16, which are known to be expressed by both conjunctival and corneal epithelial cells. These cell surface mucins act as lubricants and therefore as anti-adhesives for pathogens, preventing their adherence to the ocular surface [26]. It is considered as a restrictive barrier, though to which extent it is a barrier for topically applied drugs is still not clearly defined [27]. Nevertheless, it is known that trans-mucosal delivery can be difficult as the mucus layer may act as a filter (mesh size typically  $<1 \mu\text{m}$  [28]), while also the charge and viscoelasticity of the mucus layer might hinder drug diffusion [29]. Nevertheless, formulations with mucoadhesive features (e.g. chitosan-polyvinyl alcohol containing hydrogels [30] and sulfacetamide sodium microspheres [31]) that can interact with the mucin layer are shown to have longer retention time and improved drug absorption into the eye [31–33], suggesting the importance of this layer for drug delivery purposes and bioavailability.

As the drug dilutes into the tear film it spreads over the entire eye bulb. The complete anterior sclera and the inner side of the eyelids consist of conjunctival tissue which is, unlike the cornea, vascularized. Uptake by these tissues will in part lead to systemic absorption due to

the available blood and lymphatic vessels [17,18,34]. Altogether, these precorneal dynamic barriers contribute to a loss of  $\sim 95\%$  of topically administered drugs.


As Fig. 1B shows, the cornea consists of five layers: the epithelium, the Bowman's membrane, the stroma, the Descemet's membrane and the endothelium.

The **epithelium** comprises 5–7 cell layers in various differential stages. Corneal stem cells are located in the limbal region of the eye. They allow for a continuous renewal of the basal cells, the deepest layer of the corneal epithelium [35]. The cells, as they are pushed upwards, flatten and form tight junctions forming first wing cells and lastly superficial cells. At the level of the 2–3 outermost layers, these flattened squamous superficial cells form the biggest hurdle to drug delivery. As shown in Fig. 1C, there are three ways to cross the epithelium: (i) the transcellular pathway, dependent on drug size, charge and lipophilicity [36]; (ii) the paracellular pathway for small hydrophilic molecules as the pore diameter between cells of the corneal epithelium is  $2.0 \text{ nm} \pm 0.2$ , which only allows permeation of molecules with size  $<500 \text{ Da}$  [37]; and (iii) transporter-mediated permeation (e.g. CNT, SLC28 nucleotide transporter), which requires a high affinity of the drug to the transporter [38]. Due to the negative charge of the membrane of the epithelial cells, negatively charged particles or biologics such as nucleic acids can hardly cross this layer [39].

The **Bowman's layer** is located between the stroma and the epithelium and consists mostly of strongly layered type I and V collagen fibers. It is described as a condensation of the most anterior part of the stroma but can be distinguished from it due to a different orientation of the collagen fibers, which are randomly interwoven to form a dense sheet [40]. This layer, however, possesses relatively large pores ( $\sim 10 \mu\text{m}$ ) and is therefore not considered as a strong barrier limiting the passage of drugs or particles to the stroma [41].

The **stroma** is accountable for approximately 90% of the thickness of the cornea and strongly contributes to its transparency and rigidity. It consists primarily of water and collagen (mostly type I) that runs in the same alignment as opposed to the random orientation found in the Bowman's layer [42,43]. Due to the aqueous composition of this layer it is considered to be a strong barrier for lipophilic particles. Though, the collagen fiber sieve can also hinder the diffusion of hydrophilic macromolecules in this layer [44].

The **Descemet's membrane**, which is located between the endothelium and the stroma, functions as a protective membrane for the endothelial layer and consists mostly of type IV collagen sheets [45,46]. For trans-corneal delivery the Descemet's membrane is usually not



**Fig. 1.** (A) Schematic overview of the eye. (B) Structure of the cornea. (C) The three main pathways to cross the corneal epithelium: the transcellular pathway (i); the paracellular pathway (ii); and the transporter-mediated pathway (iii).

considered a limiting barrier since its estimated average pore size of 38 nm [47] is larger than the pores in the epithelium [41]. However, macromolecules and particles administered directly into the stroma could be prevented from reaching the endothelium [48].

The **endothelium** is a single layer of cells whose role is to maintain the water level in the stroma, thus ensuring corneal transparency and transport of nutrients. Unlike the epithelium, dead cells are not renewed in the endothelium, which makes the treatment of these cells a highly sought target for biologics. This single layer provides another minor barrier to hydrophilic particles because of the cellular composition. Even though this layer also possesses tight junctions, compared to the epithelial layer it is less limiting for drugs as it is much more leaky and discontinuous, as observed after staining with fluorescent junction markers such as ZO-1 and cadherins [49]. Due to those gaps and because the endothelium is a single cell layer, it is not considered as a significant barrier for full corneal penetration [44,50].

Important to consider as well is that when biological drugs have overcome the anatomical barriers introduced above and have reached the targeted cells, they still have to overcome (intra)cellular barriers such as the cell membrane and *endo*-lysosomal compartments, which further limits their availability and efficacy [51].

In this review, we aim to give an overview of various delivery strategies, based on either biochemical or physical methods, that have been explored to cross the corneal barriers and deliver biologics to the different layers of the cornea (i.e. the epithelium, the stroma and the endothelium) with original examples from the literature.

### 3. Delivery of biologics to the corneal epithelium

#### 3.1. (Bio)chemical methods to deliver biologics to the corneal epithelium

##### 3.1.1. 'Naked' delivery

The most straightforward way to deliver biologics in the cornea would be the topical administration of 'naked biologics', i.e. without encapsulation of the drug in a (nano)carrier. However, this way of delivering biologics presents some limitations. First, nucleic acids/proteins are not stable as they might be degraded by enzymes that are found in the tear film [52,53]. Second, naked biologics have poor interaction with the ocular surface. Besides, internalization of biologics into cells has proven to be very difficult [54]. Even after cellular uptake most will be degraded in *endo*-lysosomes before being able to exert their function [54]. Therefore, only few examples with moderate success of naked delivery have been reported. In the context of keratitis, i.e. an inflammation of the cornea that can have an infectious or traumatic origin, naked antisense oligonucleotides, preventing insulin receptor substrate-1 expression in the corneal epithelium, were topically administered to a neovascularized cornea. Though the vessels were still present in the epithelium, the relative area of neovascularization narrowed after persisted treatment for up to 6 months [55]. The company Sylentis investigated the administration of a naked siRNA for the treatment of dry eye disease. By targeting the transient receptor potential cation channel subfamily V member 1 (TRPV1), which can be found in both the corneal epithelium and the conjunctiva, it is expected to modulate sensing and transmission of pain stimuli linked to dry eye disease. In a phase I/II clinical trial, a significant improvement in symptoms commonly seen with dry eye disease, such as eye sensitivity and irritation, was observed without any side effects [56]. A phase III trial concluded in 2019 showed improvements in patients through reduced pain, dryness, and itching especially in a subgroup of patients suffering from Sjögren's Syndrome [57]. If naked delivery of biologics has shown some relative success at the level of the epithelium, strategies to further improve (intracellular) delivery of biologics on the one hand and the stability in biofluids (e.g. tear film) on the other hand, are still required.

##### 3.1.2. Cell penetrating peptides for ocular delivery


Cell penetrating peptides (CPP) are usually small peptides with a

maximal length of 30 amino acids [58]. They have a high rate of permeation into cells, while showing low cytotoxicity and no immunological response [58]. CPPs can be internalized in cells through two different mechanisms. The first mechanism is via direct membrane translocation, i.e. CPPs can form inverted micelles or pores at the level of the cell membrane. The second mechanism is based on endocytosis (e.g. macropinocytosis, clathrin-mediated endocytosis and caveolae-mediated endocytosis) (Fig. 2A). Direct translocation allows the cargo carried by the CPPs to be delivered directly into the cytoplasm, thereby avoiding (degradation in) the *endo*-lysosomal compartment [58]. Johnson et al. initially investigated different types of CPPs for retinal delivery. They synthesized a peptide with a heparin-binding region able to interact with heparin and chondroitin sulfate found at the surface of the retina [59]. To investigate whether it is possible to deliver this peptide non-invasively, they topically administered the peptide (named peptide for ocular delivery (POD)) conjugated to the fluorescent probe lissamine and observed an enhanced corneal uptake compared to lissamine only. While naked lissamine dropped on the cornea of mice did not show any significant penetration into the corneal epithelium, lissamine-conjugated POD seemed to be internalized into the epithelial cells of the cornea. Most of the fluorescence was detected in the outer layer of the epithelium indicating POD had improved contact time with the cornea. However, the fluorescence almost completely disappeared 24 h after treatment [59]. In another study, the same group conjugated a GFP tag to the POD to investigate whether also macromolecules can be delivered in this way. While the naked GFP protein did not seem to be taken up by the cells, GFP-POD fusion protein resulted in fluorescent signals in the corneal epithelial cells of mice. The fluorescence was mostly seen in the epithelial layers but a very faint signal was also detected in the most anterior part of the stroma suggesting POD might have potential to deliver peptides and proteins in various layers of the corneal epithelium [60].


Although POD is attractive for the delivery of biologics into the cytoplasm, a portion of the conjugates remains internalized into the *endo*-lysosomes where it most likely degrades [58]. Our group has recently shown that cationic amphiphilic compounds, with many of them used as drugs (e.g. antihistaminics, antidepressants, antihypertensives), are able to facilitate lysosomal escape of nucleic acid drugs [61–63]. Schirotti et al. explored other avenues to improve *endo*-lysosomal escape of siRNA carried by POD (Fig. 3) in the corneal epithelium. Either palmitoyl (PALM) or cholesteryl groups were conjugated at the N-terminus of the POD to increase the hydrophobicity of the peptides and aid in the destabilization of the endosomal membrane. This improved the delivery of fluorescently labeled siRNA in the corneal epithelium of mice. Interestingly, palmitoylation showed 3–4 times higher transfection efficiency (Fig. 4A). To further improve cytosolic delivery, they added chloroquine (a cationic amphiphilic drug known to induce lysosomal membrane permeabilization) one hour before transfecting the cells with PALM-POD complexed with anti-luciferase siRNA. The authors confirmed this improved the knockdown of luciferase *in vitro* in human corneal epithelial cells (HCE-S) [64]. As chloroquine is known for its ocular toxicity [65] it was replaced with the better tolerated trifluoromethylquinoline (QN). Functionalizing PALM-POD with this compound resulted in a significant knockdown of a luciferase reporter gene (up to 30%) *in vivo* in the corneal epithelium of transgenic mice, which could be observed for 72 h after treatment. Also, the knockdown was seen in deeper layers of the cornea suggesting this method could be employed to reach stromal cells via topical administration [64].

#### 3.2. Non-viral vectors

To improve corneal wound healing, Zahir-Jouzani et al. explored polyethylenimine (PEI) to deliver siRNA targeting TGF- $\beta$ 1 [66]. PEI is a positively charged polymer that is commonly used to form complexes with negatively charged nucleic acids [67]. In an alkali burn mouse



**Fig. 2. Biochemical and physical methods for corneal delivery of biologics.** In the right panels, green layers (epithelium, stroma and endothelium) in the cornea indicate where the different methods have been successfully used for the delivery of biologics. (A) Cell penetrating peptide can be used to deliver drugs through different types of entry into the cell: clathrin- and caveolae-independent endocytosis (i), caveolae-mediated endocytosis (ii), clathrin-dependent endocytosis (iii), macropinocytosis (iv), inverted micelle (v), barrel-stave pore (vi), toroidal pore (vii) and carpet formation (viii). (B) Viral vectors are able to enter cells by endocytosis and followed by endosomal escape (i) or by fusing with the membrane (ii). (C) Electroporation uses electric fields to transiently create pores in cell membranes which allows diffusion into the cells. (D) Gene gun delivery employs coated micro particles that are propelled under pressure towards a tissue. The high pressure allows the particles to perforate the membranes which are quickly closed after treatment. Distance between gene gun and cornea and pressure can be adjusted to target different epithelial layers. (E) Sonoporation is a method where ultrasound waves are used to cavitate microbubbles to form pores. Expansion and shrinking of bubbles under the influence of acoustic waves pull and push on the cell membrane causing transient pore formation (i). Waves are able to push bubbles against the membrane, with enough force it can cause it to be pushed through the membrane and form pores (ii). When the bubble collapses a liquid jet can be formed which punctures the membrane (iii). (F) Microneedles are able to penetrate the epithelium and enter the stroma. Microneedles are embedded in the cornea and start dissolving to release the drug (i). Drug-coated microneedles dissolve into the stroma (ii). Hollow microneedles can be used to directly inject liquid formulations into the stroma (iii). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)



**Fig. 3.** Structural representation of peptide for ocular delivery (POD) conjugates. Palm = Palmitoyl, Chol = Cholesteryl and QN = trifluoromethylquinoline (adapted from [64]).

model, after 21 days of treatment with these polyplexes, angiogenesis and fibrosis could no longer be detected. Complexing siRNA with PEI led to an improved internalization into the fibroblasts that migrate to the epithelium after corneal wounding. However, a slight inflammatory response in the treated group was observed, which was most likely attributed to PEI [66]. As PEI is generally considered as a toxic polymer, mainly due to its strong cationic charge density, it might not be an optimal excipient for ocular delivery of nucleic acids [68].

Baran-Rachwalska et al. investigated topically applied biodegradable silicon/lipid nanoparticles (SiNPs; named ProSilic) to deliver (fluorescent) siRNA into corneal epithelial cells in mice [69]. Different lipid mixtures were explored (including DOPE and DC-chol). Fluorescent siRNA was complexed to the nanoparticles, which were topically applied on a mouse cornea. Compared to naked siRNA, the uptake was twice as high and reached maximal levels already 15 min after administration. Depending on the lipids used, which changes charge and loading capacity of the silicon/lipid nanoparticles, a fluorescence signal could still be detected in the cornea after 24 h (Fig. 4B). Subsequently, luciferase-targeting siRNA packaged in ProSilic nanoparticles was topically applied daily in a reporter knock-in mouse model. A significant reduced luciferase expression could be observed within 24 h after the first administration and lasting up to four days after the end of the treatment with a maximum inhibition of 41% at day 11 [69].

### 3.3. Viral vectors


Viral vectors are commonly used for gene therapy. Their natural ability to transduce genetic information into host cells can be exploited by exchanging their genes by transgenes of choice (Fig. 2B). Many types of viruses are of interest e.g. retrovirus, lentivirus, adenovirus and herpes simplex virus, each showing advantages and drawbacks (i.e. gene capacity, immunogenicity, tropism, being able to transduce non-dividing cells) [70]. In recent years, several drugs using viral vectors were approved, including Luxturna (AAV2 vector subretinally injected in patients with a biallelic RPE65 mutation-associated retinal dystrophy,

such as Leber's congenital amaurosis [71]), Zolgensma (AAV9 vector intravenously infused to treat spinal muscular atrophy [72]) and Zyn-teglo (intravenous infusion of a lentiviral vector for the treatment of beta thalassemia [73]). A main concern of viral vectors, however, is related to their immunogenicity and cytotoxicity. Other concerns are the large scale GMP manufacturing costs and [74] the possible mutational insertions which can lead to activation of proto-oncogenes or insertional inactivation of tumor suppressors genes. Though, as the transfection efficiency of viral vectors is high compared to non-viral vectors [70], viral vectors remain attractive for ocular (including corneal) gene delivery.

Delivering a reporter gene in an adenovirus vector by eye drops has shown disappointing results since mostly no or poor expression could be observed in the corneal epithelium or in the conjunctival cells [75,76]. This can be likely explained by the fact that the vectors stayed entrapped into the mucin layer. Indeed, Tsubota et al. showed that mechanically removing the mucus layer of the corneal surface with a cotton swab resulted in a better expression of the reporter gene lacZ when delivered with an adenovirus (AV) type 5 in the conjunctival cells but not in the corneal epithelium [75]. Reaching higher expression levels in the corneal epithelium would likely require higher AV concentrations, which could possibly lead to toxic levels in the conjunctival cells as these cells are more easily transfected [75].

In a similar experiment, Spencer et al. treated intact mouse and rat eyes in vivo with a Herpes simplex virus-1 vector expressing lacZ and observed no expression after topical administration. However, when scarring the cornea with a 30-gauge needle before treatment, expression of lacZ was observed in the epithelial layer of both mice and rats [77].

In an effort to improve residence time and transfection efficiency of topically applied adenoviruses, Wang et al. functionalized adenoviruses with chitosan [76]. Indeed, it is known that chitosan, owing to its mucoadhesive properties, prolongs residence time of e.g. polymeric nanoparticles at the surface of the eye [78,79]. This modified vector was used to deliver GFP-encoding pDNA in vivo into the epithelial cells of rats. Rats treated with the chitosan-conjugated vector showed a more



**Fig. 4. Delivery of biologics into the corneal epithelium.** (A) POD (being peptides for ocular delivery) are able to efficiently deliver fluorescently labeled siRNA (siGLO, red signal) into the epithelial layer of the cornea; naked siGLO (right panel) does not transfect the epithelial cells [64]. (B) 24 h after treatment silicon/lipid nanoparticles (ProSilic) successfully transfected corneal epithelial cells (red fluorescent siGLO) when DOPE:DC-cholesterol:stearylamine were used as lipids [69]. (C) Luciferase expression is clearly visible in the corneal epithelium following electroporation of the cornea [82]. (D) Following gene gun treatment, gold particles (black dots) are able to penetrate different layers of the corneal epithelium (original magnification  $\times 250$ ) [87]. Adapted from [64,69,82,87]. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

intense fluorescent signal along the full corneal epithelium, relative to its unmodified counterpart [76].

### 3.4. Physical methods to deliver biologics to the corneal epithelium

Using physical methods (i.e. involving external stimuli such as pressure, ultrasound, electric fields), it might be possible to efficiently

bypass the tear film and the tight junctions of the epithelium, while also improving the (intracellular) delivery of biologics.

#### 3.4.1. Electroporation

Electroporation applies an electric field to form pores in cell membranes. The cell membrane has a low electric potential. Therefore by increasing the transmembrane potential with short low electric pulses, it

is possible to (transiently) re-orientate membrane lipids, thereby forming small pores that allow molecules to diffuse into cells [80,81] (Fig. 2C). Electroporation over the anterior section of the cornea following intrastromal injection of pDNA has been successful in expressing luciferase and IL-10 in the epithelium layer [82,83]. Expression of luciferase could be detected as early as 6 h post treatment, across the entire cornea. Blair-Parks et al. also investigated the effectiveness of epithelial transfection with electroporation after a subconjunctival or an intrastromal injection of luciferase pDNA in mice. Electroporation after subconjunctival injection led to a higher initial expression of luciferase in several layers of the epithelium, albeit it showed a faster decline compared to intrastromal injection. With both injection methods, luciferase expression was still detected after 7 days (Fig. 4C). While a voltage of 200 V/cm was sufficient to achieve delivery without inducing ocular tissue damage, higher voltages ( $\geq 400$  V/cm) led to visible damages such as corneal edema [82].

#### 3.4.2. Gene gun

Gene gun is mostly employed to deliver nucleic acids into cells [84]. Though gene gun has been extensively studied *in vitro* to transfect cells, it has also been investigated for *in vivo* transfection of corneal epithelial cells [85–90]. Gene gun uses nano- or microparticles, usually gold, coated with nucleotides that will be propelled into cells or tissues. An inert gas such as helium is used to propel the particles allowing them to penetrate cell membranes or travel through a tissue [91] (Fig. 2D). Exploring gene gun for transfection of corneal epithelium, Zhang et al. observed that it is critical to adjust both the distance between the nozzle and the front of the eye and the force applied on the drug loaded particles. Important to mention is that wrong settings (e.g. high pressure) may permanently damage corneal tissue leading to erosion and neovascularization [86]. As one can expect, a longer distance between the gene gun and the cornea causes less severe defects of the corneal surface [86] and allows spontaneous recovery. Higher forces led to a deeper penetration of the particles in the corneal epithelium [86]. Besides crossing barriers, a strong advantage of gene gun is the possibility to bypass lysosomal degradation through direct delivery into the cytosol [91]. Successful gene gun experiments showed delivery of plasmid DNA encoding for interleukins (IL) in the epithelium [86,87]. Bauer et al. succeeded in expressing IL-4 and IL-10 to moderate the progress of herpetic stromal keratitis without interfering with other local immune responses [87]. These authors observed that gene gun treatment can lead to a mild inflammation in the limbal region. Most of the particles (respectively 0.6  $\mu\text{m}$  and 1.6  $\mu\text{m}$ ) were found in the epithelial layers with some in the anterior segment of the stroma (Fig. 4D). It was also noticed that, after 14 days, most of the gold particles were cleared from the epithelium, probably due to the high turnover rate of epithelial cells [87]. In both studies, production of ILs by corneal epithelial cells could be induced without any serious side effects. All these examples showed gene gun delivery leads to very local delivery without affecting other tissues and might thus be well suited for delivering biologics to the corneal epithelium.

## 4. Delivery of biologics to the stroma

Reaching the stroma after topical administration of drugs is generally difficult because of the upstream epithelial barriers. However, it is an interesting target as it is where several dystrophies originate, e.g. congenital stromal corneal dystrophy (decorin gene), macular corneal dystrophy (carbohydrate sulfotransferase 6 gene) and Fleck corneal dystrophy (phosphoinositide kinase gene) [11]. The main cellular targets are the keratocytes, which are able, in response to damage, to differentiate into repair fibroblasts [13]. The stroma is also an important therapeutic target for treating neovascularization as it is the siege of many of the newly formed blood vessels [92].

### 4.1. (Bio)chemical methods to deliver biologics to the stroma

#### 4.1.1. Naked delivery

During corneal neovascularization (due to e.g. trauma, infection and inflammation), new vessels originate from the capillaries and venules of the pericorneal plexus under the influence of pro-angiogenic factors such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor and matrix metalloproteinases. Rapid therapeutic management is important, as when new blood vessels are making their way into the stroma it loses its transparency. VEGF is seen as an interesting therapeutic target as it plays an important role in vessel formation [92]. In the stroma, VEGF is primarily produced by inflammatory cells such as macrophages but it can also be produced by keratocytes during inflammation [93]. To inhibit neovascularization, Zuo et al. subconjunctivally injected naked siRNA against VEGF-A in an alkali burn mouse model. They showed reduced VEGF levels compared to saline injections, hence downsizing the neovascularized area and vessel formation in the stroma. This effect was observed until the end of the study (30 days) [94]. Singh et al. investigated a similar setup, using naked siRNA against VEGF in an alkali burn mouse model, but this time injected intrastromally. A week after injury, VEGF levels were decreased ( $> 50\%$ ) compared to control mice and the neovascularized area was significantly smaller [95].

#### 4.1.2. Non-viral vectors

As neovascularization leads to new blood vessels in the stroma, Kim et al. suggested to reach the stroma via systemic administration of drugs [96]. Indeed, the leakiness of blood vessels in tumors and inflamed tissues has been well investigated [97,98] and it is believed that it may locally enhance extravasation of drugs. These authors compared subconjunctival and systemic injections of respectively naked siRNA and siRNA nanoencapsulated in TargeTran (i.e. PEG-conjugated-PEI coupled with RGD [99]) with the aim to deliver a cocktail of 3 siRNA's against the VEGF pathway factors VEGFA, VEGFR1 and VEGFR2. TargeTran was previously successfully used in studies to deliver siRNA targeting tumor angiogenesis [96]. Both methods led to the inhibition of new blood vessel formation, although subconjunctival treatment was more effective likely due to opsonization and first pass degradation following systemic administration. Rodier et al. used linearized PEI to form polyplexes with GFP-pDNA. As it is difficult to cross the corneal epithelium, the authors removed the epithelium layer of the mice. While topical application of naked pDNA did not transfect the cells, the topically applied polyplexes were able to transfect keratocytes in the anterior and middle part of stroma [100].

Luis de Redín et al. investigated the use of albumin nanoparticles to improve topical delivery of bevacizumab to reach the stroma using a chemical burn rat model. [101] Bevacizumab targets VEGF and is used to inhibit neoangiogenesis in cancers. However, it is also used as an off label drug in the treatment of corneal neovascularization [102] and neovascular age-related macular degeneration for which it is intravitreally injected [103]. Topically applied naked bevacizumab reduced the area affected by neovascularization by 11% at day 7. When encapsulated in albumin nanoparticles or PEG-albumin nanoparticles the affected area decreased by 61% and 38%, respectively. This might be due to the albumin particles being able to adhere to the mucus layer. The authors argued that PEGylating the particles probably slightly hindered this interaction which might explain the lower effect [101].

In another example, Sun et al. investigated whether mesoporous silica nanoparticles could improve delivery of bevacizumab in the stroma in an alkali burn mouse model. Free bevacizumab and encapsulated bevacizumab were injected subconjunctivally, which led to a reduction of vascular length around 80% and 90% respectively at day 14. Due to the porous nature of the particles the bevacizumab was slowly released from the particles explaining the improved efficacy compared to free bevacizumab [104].

#### 4.1.3. Viral vectors

As reported above, administering drugs directly into the stroma is possible via intrastromal injection. For this purpose, Carlson et al. explored adenoviral carriers that were intrastromally injected in mice to transfect stromal keratocytes with GFP pDNA. GFP could be observed in the stroma 11 h after a single injection while a faint GFP signal could still be detected on day 21. Following intrastromal injection of naked pDNA also keratocytes became transfected though GFP expression was found to be lower. Authors suggested that the injection of naked pDNA transfected keratocytes due the pressure at the injection spot, which might permeabilize the keratocytes to some extent. Though the Descemet's and Bowman's membranes are usually not seen as barriers, no GFP signal could be detected neither in the epithelium nor in the endothelium in this study [105].

To improve stromal cell transfection following intrastromal injection, Lu et al. investigated 14 different serotypes of rAAV expressing eGFP in mice. The serotypes differed in their capsid proteins, possibly altering their means of entry into cells. Authors found that serotypes rAAVrh.8, rAAVrh.10, rAAVrh.39, and rAAVrh.43 were able to efficiently transduce keratocytes after intrastromal injection. These 4 serotypes were then investigated in their ability to transfect keratocytes following topical administration. It was found that topical administration on corneas with intact epithelium did not lead to any transfection. After scraping the epithelium, the serotypes rAAVrh.10 and rAAVrh.39 were shown to pass the Bowman's membrane and able to successfully transfect keratocytes in the stroma without adverse effects [106]. In a follow-up study, the same group compared intrastromal and subconjunctival injections of rAAVrh.10 vectors in an alkali burned induced neovascularization mouse model. In both healthy and damaged mouse corneas, eGFP signal was observed for a week after treatment, with both administration routes proving to be equally effective. However, two weeks after administration, the expression in damaged cornea was drastically lower than in healthy corneas (Fig. 5A). With the knowledge that in the first week of treatment transfection is still effective, they delivered microRNAs (miRNA) through rAAVrh.10 vectors against genes (hey2, gjc1, rasip1, and amot) involved in neovascularization. Both administration routes allowed the miRNA to reach the entire cornea and to normalize the biological pathways that led to vascularization, thus resulting in a significant decrease of vascularized areas. However, as neovascularization originates from the limbal area, subconjunctival injections are preferred as newly forming vessels can directly be addressed likely due to the proximity of the subconjunctival tissue to the limbus [107]. Also Hippert et al. showed that the serotype of adeno-associated viruses influences transduction of cells after intrastromal injection. When examining 4 AAV2 types, the subtype AAV2/8 was found to be most efficient in transfecting keratocytes with eGFP pDNA in mice. eGFP expression in the stromal cells was still visible until 17 months after a single injection. Interestingly, eGFP expression could get a temporary boost after a sequential injection of both lipopolysaccharides (LPS) but also PBS. The authors argue that the injection itself causes an inflammatory response, able to promote gene expression levels [108]. The exact mechanism behind this remains unknown, however, in an earlier study Tsai et al. noticed this effect as well in the endothelial layer. They hypothesized that AAV-mediated gene expression is facilitated by the host cell's DNA repair process as a result of inflammatory DNA damage [109].

As seen above, intrastromal injection is of interest. However, this type of injection presents some variability as often a poor repeatability is observed. Gilger et al. investigated if by using a microsized needle these variations can be overcome. First, they investigated stainless steel microsized needles of various lengths in an ex vivo porcine eye. Depending on the length of this type of needle different depths in the stroma could be reached. They then compared intrastromal injections of AAV vectors (GFP pDNA) with a 8 mm needle to injections with a microsized needle (318  $\mu\text{m}$  long) in rabbits. No significant difference was observed in GFP expression between the two methods. However,

injections with microsized needles were more accurate and led to less anterior chamber penetration and leakage, which further strengthens the possibility to lower the variability and improve safety of intrastromal delivery [110].

Gupta et al. used an AAV5 vector to topically deliver the Smad7 gene to stromal cells to inhibit corneal haze formation after photorefractive keratectomy. Hereto a rabbit corneal injury model with an epithelium scraped cornea was applied. The Smad7 protein negatively regulated TGF $\beta$  signaling during corneal wound healing. In an injured state, the TGF $\beta$  downstream signaling is altered, which results in corneal scarring. Both treated and non-treated eyes showed a corneal haze, albeit treated eyes showed relatively less cloudiness and haze. A reduced expression of  $\alpha$ -SMA and fibronectin (two markers of scar formation) were observed in the treated group 4 weeks after treatment, suggesting the vectors successfully reached their target. This treatment seemed safe as no immune cell infiltration could be detected [111].

Finally, Yu et al. showed recombinant adenoviruses injected into the aqueous humor were also able to reach the stroma. This suggests adenoviruses are able to cross the endothelial layer and the Descemet's membrane in corneas with neovascularization [112].

## 4.2. Physical methods to deliver biologics to the stroma

### 4.2.1. Sonoporation

Ultrasound has been established as noninvasive and safe clinical imaging tool for decades. Sonoporation makes use of such ultrasound waves to porate cells and deliver cargos into cells [113,114]. Also microbubble-assisted sonoporation is under investigation for drug delivery [115]. Under the influence of ultrasound waves the gas core of the microbubbles can shrink and grow. Both the pressure of such stably oscillating bubbles as well as the force generated when the microbubbles collapse can be harnessed to create pores in cell membranes [113,114] (Fig. 2E).




Sonoda et al. injected a mixture of microbubbles and GFP pDNA into the stroma of rabbits to transfect keratocytes. Applying ultrasound, the microbubbles were oscillating, which improved the transfection of keratocytes. Using low intensities (<2 W/cm<sup>2</sup>), no apparent damages were observed at the level of the stroma or surrounding tissues and most of the transfected cells were located around the injection spot (Fig. 5B) [116]. Increasing the ultrasound intensity (>3 W/cm<sup>2</sup>) induced stromal opacity but this was resolved without any further treatment. The transfected cells displayed increasing GFP expression for 8 days after which the GFP expression decreased slowly and disappeared completely 30 days after treatment [116].

### 4.2.2. Electroporation

Applying electric pulses after an intrastromal administration of pDNA has successfully transfected keratocytes [82,117]. As reported above, Blair-Parks et al. investigated corneal transfection with electroporation following an intrastromal injection of naked luciferase pDNA in mice. In this way they were not only able to transfect the corneal epithelium but also stromal cells. Expression could be detected 7 days after the treatment. A voltage of 200 V/cm for 10 ms was sufficient to achieve delivery without inducing ocular tissue damage [82]. Oshima et al. could also detect GFP expression in the stroma of rats for up until 15 days using 20 V pulses (50 ms) without any apparent damage after an intrastromal injection of naked GFP pDNA. Increasing the voltage above 40 V/cm increased the number of inflammatory cells and led to neovascularization [117].

### 4.2.3. Microneedles

Kim et al. investigated the potential of microneedles in delivering the monoclonal antibody bevacizumab into the stroma of rabbits. They induced neovascularization by inserting a silk suture into the stroma near the limbus. Solid microneedles (Fig. 2F) (400  $\mu\text{m}$  in length, 150  $\mu\text{m}$  in width, 75  $\mu\text{m}$  in thickness) were coated with labeled and non-labeled



(caption on next page)

**Fig. 5. Delivery of biologics to the stroma.** (A) Fluorescence images of the cornea following respectively intrastromal and subconjunctival injections of rAAVrh.10 eGFP vectors. In both healthy and damaged mouse corneas eGFP signal was observed in the stroma for a week after treatment. IS and SC injections proved to be equally effective [107]. (B) GFP expression is clearly visible (in the corneal section; right panel) after intrastromal injection of naked pDNA and microbubbles followed by ultrasound treatment. Arrows show the injection spot of the pDNA and microbubbles. Arrowheads show the location of the ultrasound probe [116]. (C) Signal of red fluorescently labeled IgG was still visible in the stroma of mice after removal of solvable microneedles indicating successful stromal delivery [119]. (D) Laser-assisted treatment of the stroma is able to create pockets visible as lines running through the cornea (white arrowheads in the left panel). These pockets encompass the whole corneal area, which is clearly visible after fluorescein injection (middle panel). Three days after injecting a lentivirus encoding for GFP, transfected keratocytes are clearly visible, nuclei are stained in blue (right panel) [130]. Adapted from [107,116,119,131]. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

bevacizumab and were compared with topical administration and subconjunctival injection. Microneedles and subconjunctival delivery both led to the highest reduction of neovascularization (65% and 62% at day 10 and 62% and 29% at day 18 respectively) compared to non-coated microneedles (i.e. without bevacizumab). However, the dose needed to reach this effect with a subconjunctival injection was more than 550 times higher than the one delivered with the microneedles. Also, hollow microneedles, which can be filled with a drug solution in their core, were compared to coated solid needles. Though the amount of bevacizumab that could be administered with hollow needles (50 µg) was higher than with coated microneedles (4.4 µg), reduction of the vascularized area did not improve further. The authors argued this could be due to the spreading of the solution after administration while the solid microneedles slowly dissolve, the latter which maintains high bevacizumab levels more locally in the critical area. The microneedles did not induce corneal opacification or any other visible adverse effects [118].

As another example, Than et al. investigated ‘double layered’ microneedles. Microneedles can be made from hyaluronic acid, albeit they dissolve fast resulting in a burst release of the drug. Functionalizing hyaluronic acid with methacrylic anhydride provides a slower release, however, the stiffness of such microneedles is not optimal. The authors therefore proposed to design microneedles with a rigid fast dissolving core and an outer shell allowing a slower release. Such microneedles were embedded in the cornea aimed to act as a depot (Fig. 5C). DC101 (an anti-VEGFR2 monoclonal antibody) was incorporated between the fast bursting core and the slow release outer shell (Fig. 2F). In a chemical burn mouse model, treated eyes showed a reduction of 90% of the vascularized area while topical administration only led to a reduction of 44% compared to non-treated eyes. Subsequently diclofenac was incorporated in the fast dissolving core while the shell was loaded with DC101. This combination therapy led to a vascularized area of 0.16 mm<sup>2</sup> while diclofenac only and DC101 only resulted in a vascularized area of 0.63 mm<sup>2</sup> and 0.52 mm<sup>2</sup>, respectively. There were no visible adverse effects such as opacity, inflammation or hemorrhage found in the cornea after treatment [119].

#### 4.2.4. Gene gun

As reported above, gene gun at higher pressure can lead to deeper penetration of (gold) nanoparticles in the cornea [87,88]. Only few examples report on gene gun for the delivery of biologics into the stroma. For instance, Shiraishi et al. observed pDNA-coated gold nano- and microparticles (respectively 0.6 µm and 1.6 µm) only in the anterior part of the stroma. Authors explained that the high density of collagen fibers in the stroma, but also the low amount of keratocytes, limit the probability that cells in the stroma become affected by the particles. Authors therefore concluded that gene gun is not a promising approach to efficiently transfect stromal cells [88].

#### 4.2.5. Light-based delivery

Pulsed-lasers and more particularly femtosecond lasers are commonly used in ophthalmology to ablate tissues (e.g. for corneal ablation [120] or cataract surgery [121,122]). Even though they have been shown to transfect retinal ganglion cells in vivo [123] or to destroy vitreous opacities ex vivo (i.e. vitreous floaters) [124], surprisingly only few examples on the exploration of light for corneal drug delivery are

reported.

Using pulsed-lasers it is possible to form (transient) pores in cell membranes, which is under investigation to deliver cargos in cells [125–127]. Also, pulsed-lasers are under investigation to form pores in tissues such as nails [128] and skin [129]. Bemelmans et al. followed this idea to form a ‘pocket’ in the stroma to serve as a reservoir for lentiviral vectors. After the pocket was created at a depth of 110 µm from the epithelium, lentiviral vectors expressing GFP were injected into it. The pockets were naturally closed after 5 days. Lentiviral vectors expressing GFP and injected in the pocket could transduce 90% of the keratocytes surrounding the pocket whereas 53% of the keratocytes were transduced after intrastromal injection (Fig. 5D) [131]. Interestingly, the expression was still visible after 21 days. However, in this study, the authors did not mention the laser fluence that was applied. Pallikaris et al. described a case study where a similar ‘corneal pocket’ close to a corneal abscess was created in a patient to treat a recurring deep stromal keratitis [131]. This facilitated direct delivery of antibiotics and an antifungal therapy, which after standard topical application had no effect. Therefore, a 380 µm deep pocket was created using a laser energy of 1.3 µJ. The compounds, moxifloxacin and voriconazole, were then injected into the pocket. Improvements such as less dense abscesses, less edema in surrounding tissues and absence of epithelial defects were observed after 5 days suggesting this type of strategy has merit and could be further investigated for the delivery of biologics into the stroma, especially to induce local sustained release.

## 5. Delivery of biologics to the corneal endothelium

Being the deepest layer of the cornea, the endothelium remains difficult to reach after topical administration. Since it is adjacent to the aqueous humor, it is possible to evade many barriers through intracameral injection (i.e. into the aqueous humor) of drugs. The aqueous humor possesses a dynamic barrier due to passive fluid flows (2.4 ± 0.6 µl/min). A first fluid flow is due to a pressure gradient that moves the aqueous humor through the trabecular meshwork into Schlemm’s canal and finally into the draining collector channels. In the second flow (the uveoscleral pathway), the fluid flows through the ciliary muscles into the supraciliary and suprachoroidal spaces and finally leaves the eye through scleral channels and veins [67]. These fluid flows accelerate the clearance after intracameral injection and thus reduce the availability of injected drugs. Another drawback is that the aqueous humor is in contact with other tissues and several reports show that the trabecular meshwork, the iris and even the lens can be transfected after intracameral injection [132–134]. If the endothelial layer is compromised it often leads to corneal blindness, making it an important therapeutic target despite the challenges to reach it.

### 5.1. (Bio)chemical methods

#### 5.1.1. Naked delivery

Recently, the company Sylentis has shown promising outcomes and reached clinical trials stage IIB (last update 2016 [136]) with topically applied (naked) siRNA targeting the Adrenergic Receptor beta-2 which is involved in glaucoma and intraocular pressure. This receptor is only present in the endothelial layer. Five minutes after instilling siRNA in the eyes of rabbits it could be detected (post-mortem using a

complementary fluorescent strand) in the cornea as well as in the ciliary body and the aqueous humor. The effect lasted longer than the standard care anti-glaucoma drugs latanoprost and dorzolamide and reached its maximum potency after 4 days. Interestingly, authors concluded that naked siRNA degrades slower in the aqueous humor than in serum, giving it time to distribute to the surrounding tissues [137]. Results from the IIB trial indicated a lowering of intraocular pressure in open-angle glaucoma patients, without adverse events [136].


Chau et al. described the delivery of (naked) antisense oligonucleotides against Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT1) in C57BL6J mice. MALAT1 is a noncoding nuclear RNA target that is also expressed in the corneal endothelium. They investigated knockdown of MALAT1 and observed a reduced expression of MALAT1 (of ~60%) after both intravitreal and intracameral injection of MALAT1-targeting antisense oligonucleotides [138].

### 5.1.2. Viral vectors

Budenz et al. used recombinant adenoviruses to deliver the reporter gene lacZ to the corneal endothelium and the trabecular meshwork in mice. Injections were performed intracamerally and intravitreally. Transfection of the endothelium was visible in both cases. However, injection into the aqueous humor was favorable as the endothelium of all eyes injected intracamerally showed expression while only 2 out of 3 of the intravitreally injected eyes did. In both cases, the expression did not

last more than 14 days [133]. Tsai et al. used the same carrier but looked at the influence of inflammatory responses in a rabbit model. By inducing an inflammatory response by an intravitreal injection of lipopolysaccharides, they observed a drastic increase in eGFP expression in the corneal endothelium as opposed to a normal situation (i.e. without inflammation). When the inflammation stopped, the expression also decreased. By inducing the inflammatory response a second time the expression could be increased again (Fig. 6A). As mentioned before, the process behind this observation is still unclear, however, there could be a boost of rAAV-mediated gene expression as DNA repair is stimulated through inflammation and gene expression is promoted by DNA repair [109].

A different approach with viral vectors was investigated in donor tissues. The rationale behind ex vivo transfection of excised corneas is that many donor corneas are discarded before transplantation due to a low endothelial cell count [138]. The ability to transfect the endothelial layer (to induce cell growth) while in a tissue bank storage might increase the quality and availability of tissues. Hudde et al. investigated rAAV and recombinant herpes simplex viruses (rHSV) to deliver the reporter gene lacZ into the corneal endothelium of rabbit and human cornea ex vivo. The vector rAAV showed only 2% of the endothelial cells transfected in both species. The signal lasted up until 4 weeks, which is also the maximum duration transplants are stored. rHSV showed 5% of the corneal endothelial cells transfected but had a maximum expression



**Fig. 6. Delivery of biologics to the endothelium.** (A) After expression of lacZ was no longer detectable (left panel), administrating LPS led to the reactivation of lacZ expression (middle panel). This expression was at least detectable for 5 days after LPS boost (right panel). In blue lacZ counterstained with X-Gal is visible [109]. (B) Intracameral injection of lentiviruses with pDNA coding for GFP leads to expression in the endothelium up to 6 weeks after treatment [135]. (C) After an intracameral injection of a pDNA coding for the reporter gene lacZ followed by electroporation, a clear expression (in blue) could be seen in the endothelium 3 days after treatment (left panel). The expression in the cornea is clustered around the spot where the pulses were delivered via a ring-shaped electrode placed on the cornea (right panel) [143]. Adapted from [109,135,144]. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

after 1 day, which declined to low levels after a week. rHSV also displayed cytotoxicity, which thus needs to be addressed before being a viable therapeutic option [140]. Lai et al. used an rAAV2 vector with a CMV promoter and saw transfection in 90% of the endothelial cells which remained stable for up to 2 weeks. They argued that the differences in transfection efficiency between their study and the one of Hudde et al. could be attributed to the usage of a growth factor-enriched medium that improved endothelial cell survival [141].

Lentiviruses are interesting for the transfection of endothelial cells as they are capable of transfecting non-dividing cells. These vectors show generally lower immunogenicity and longer expression [141]. Bainbridge et al. used a lentiviral vector to deliver a GFP plasmid through an intracameral injection in C57Bl-6 J mice. This led to a stable expression of GFP 7 days after treatment across two-thirds of the corneal diameter in the endothelial layer, and being still detectable after 12 weeks (Fig. 6B). No inflammatory response was observed with this lentivirus [135]. A similar experiment was performed by Yu et al. in an alkali burn neovascularized rat model using a recombinant adenoviral vector. After intracameral injection, they observed expression of sFlk-1, a receptor capable of binding VEGF and mitigating activation of VEGF receptors, for at least 2 weeks [112].

## 5.2. Physical methods

### 5.2.1. Electroporation

Oshima et al. showed delivering pDNA coding for lacZ to the endothelium was possible using electric pulses [143,144]. Naked pDNA was injected into the aqueous humor of adult rats, albeit without transfecting the endothelial cells. By applying electric pulses to the endothelial layer (via a ring-shaped electrode placed on the cornea), the injected pDNA effectively transfected the endothelial cells (Fig. 6C). Eight electric pulses of 20 V (50 ms) showed successful gene transfection without apparent cell or corneal damage and inflammation. Higher voltage (40 V or higher) led to corneal opacity after 3 days. Interestingly, since the electric pulses were very locally applied, no other tissues showed transfection. However, transfection was predominantly observed in the periphery of the endothelial layer (i.e. outside of the visual axis), leaving room for improvement as clear vision in the pupillary zone of the endothelium is most important. Highest expression was seen on days 1 and 3 after injection, indicating the need to repeat the treatment to prolong the effect [144]. Different research groups reported that injecting pDNA intrastromally followed by electroporation did not lead to significant expression in the endothelial layer [82,83,117]. Though the Descemet's membrane is not considered as a barrier, it seems pDNA might have difficulties to cross it. Also the application of electric pulses did not seem to sufficiently affect the membrane to allow the passage of pDNA.

### 5.2.2. Gene gun

As outlined above, it is unlikely that gene gun therapy is suitable to deliver biologics in corneal endothelial cells due to its relatively long distance (~550  $\mu\text{m}$ ) from the cornea [88]. However, Klebe et al. investigated gene gun delivery on these cells in an ovine ex vivo setting by shooting from the posterior side (at a distance of 4.5 cm from the endothelium). By directly targeting the endothelial cells, they found that the endothelial layer became irreversibly damaged. The gold micro-particles were able to damage the nuclei thus inducing cell death. The transfection of the remaining living cells was found to be very low (<0.1%) confirming that gene gun is not the preferred method for transfecting the corneal endothelium [145].

## 6. Discussion

As described above, in last decades many research efforts have been undertaken to deliver biologics (especially nucleic acids) in the cornea, with varying degrees of success (Table 1). However, besides the off label

use of bevacizumab against corneal neovascularization, today biologics for corneal treatment could not reach the market. Though, at first glance, the structure and location of the cornea might allow easy delivery of biologics, it consists of many complex barriers. Original and innovative methods are therefore needed to improve the crossing of the barriers and allow efficient delivery of biologics.

Clearly, the simplest way to deliver biologics in the cornea is through administering 'naked' biologics. Also, as no other foreign materials are used it is also considered to be most safe. However, delivering naked biologics is mostly inefficient as their capacity to cross the biological barriers is rather low. To overcome these barriers, non-viral carriers are promising as several examples showed improved transfection of corneal cells when compared to naked delivery. Important to note is that non-viral carriers for biologics become more and more approved by health agencies, though for targets different from the eye. This is illustrated with the approval of Onpattro, the first lipid based non-viral carrier loaded with siRNA, which is intravenously injected to treat polyneuropathy of hereditary transthyretin-mediated amyloidosis [145]. Attractive as well is the possibility to modulate the physico-chemical properties of non-viral carriers, this e.g. to prolong their residence time at the surface of the eye (like through surface functionalization with chitosan [78,79]). Besides corneal barriers, which still remain difficult to cross with non-viral carriers, a strong challenge remains in the capacity to bypass intracellular barriers, like the *endo*-lysosomal compartment and avoid degradation of the biological cargo. This has been extensively studied using carriers that contain fusogenic compounds (like DOPE and penetrating peptides) or cationic amphiphilic molecules like chloroquine which has been also studied in the context of corneal drug delivery [64]. Despite the flexibility and versatility non-viral carriers can offer, short-term transfections are often observed, which suggests more frequent injections, reduced compliance and safety. In contrast, viral vectors (like AAV and herpes virus) can provide more durable effects lasting for months for which, however, concerns about immunogenicity and toxicity remain [146]. To obtain the best of both worlds and thus taking advantages of both viral vectors and non-viral carriers, it could be attractive to functionalize viruses with targeting or mucoadhesive compounds to increase their residence time after topical application, as reported by Wang et al. with chitosan-modified adenoviruses [76].

While much work remains to be done, physical methods might become promising to deliver biologics in the cornea. For instance, with gene gun, it is possible to precisely deliver cargos without affecting neighboring tissues. Gene gun is, however, only usable for targeting superficial tissues such as the corneal epithelium. As gene gun allows to overcome both superficial extracellular barriers of the cornea (tear film, mucus layer) and intracellular barriers (through direct delivery in the cytosol), it remains attractive. However, it is still debated whether or not gold particles are completely safe to use [147]. Therefore, replacing gold particles with biodegradable particles could be a promising solution as reported for transdermal drug delivery [148,149]. Also sonoporation allows to deliver biologics directly into the cytosol of cells. However, depending on the experimental settings, applying ultrasound might generate heat [113] that might damage the cornea. Indeed, heating up collagen fibers in the stroma may cause an immediate opacification that reverts only after a few weeks to months [150]. This risk also has to be considered when exploring light- and electroporation based methods for delivering biologics in the cornea.

Clearly, most of the biologics investigated for corneal delivery are nucleic acids (like siRNA and pDNA) while only few groups focus on corneal delivery of proteins (like antibodies), which remains a huge challenge. Proteins do not easily cross corneal barriers [151] while they are at risk of degradation [152]. Some groups explored nanocarriers [101,104] and microneedles [118] for the corneal delivery of bevacizumab and DC101 in the treatment of corneal neovascularization. Microneedles became an interesting alternative to conventional injections as they might allow larger molecules (and even adenoviruses

**Table 1**  
 Overview of the delivery of biologics into the different layers of the cornea. POC = Proof of concept; TRPV1 = transient receptor potential cation channel subfamily V member 1; MALAT1 = Metastasis-Associated Lung Adenocarcinoma Transcript 1; rAAV = Recombinant adeno-associated viruses; AAV = Adeno-associated viruses; rAV = Recombinant adenovirus; rHSV = recombinant herpes simplex viruses.

Bio(chemical)	Cargo	MW Cargo	Size Carrier	Target	Disease	Delivery type/ administration	Primary outcome	Tested in	Reference	
<b>Epithelium</b>	Naked delivery	Antisense oligonucleotide	7 kDa	–	insulin receptor substrate-1	Keratitis	Topical administration	The relative area of neovascularization in epithelium narrowed when treated.	Human	Cursiefen et al. [55]
		siRNA	~ 13 kDa	–	TRPV1	Dry eye disease	Topical administration	Symptoms of dry eye disease improved with treatment.	Human	Benitez-Del-Castillo et al. [56]
		siRNA	~ 13 kDa	–	TRPV1	Dry eye disease	Topical administration	Reduced symptoms of dry eye disease, especially in patients suffering from Sjögren's Syndrome.	Human	Gonzales et al. [135]
	Cell Penetrating Peptides	Lissamine	4 kDa	–	Epithelial cells	POC	Cell penetrating peptide	Lissamine-conjugated POD was internalized into the epithelium unlike free lissamine.	Mice	Johnson et al. [59]
		GFP Protein	32 kDa	–	Epithelial cells	POC	Cell penetrating peptide	The GFP-POD fusion protein resulted in epithelial uptake unlike GFP alone.	Mice	Johnson et al. [60]
		siRNA	~ 13 kDa	107 nm	luciferase reporter gene	POC	Cell penetrating peptide after CAD treatment	Knockdown of luciferase could be seen up to 72 h after treatment.	Mice	Schirotti et al. [64]
	Non-viral vector	siRNA	~ 13 kDa	158 nm	TGF-β1	Chemical injuries	PEI polyplexes	Angiogenesis and fibroses could no longer be detected 21 days after treatment.	Mice	Zahir-Jouzdani et al. [66]
		siRNA	~ 13 kDa	397 nm	luciferase reporter gene	POC	biodegradable silicon/lipid nanoparticles (ProSilic®)	A maximum 41% knockdown of luciferase at day 11.	Mice	Baran-Rachwalska et al. [69]
		Viral Vector	lacZ gene	3,1 kb	~ 90 nm	Epithelial cells	POC	Adenovirus type 5	The epithelium was not transfected by the vector, however the conjunctiva was.	Rats
	<b>Stroma</b>	Naked delivery	siRNA	~ 13 kDa	–	VEGF-A	Neovascularization	Subconjunctival injection	VEGF levels were reduced and the neovascularized area shrunk after treatment.	Mice
siRNA			~ 13 kDa	–	VEGF	Neovascularization	Intrastromal injection	Decrease of VEGF levels and neovascularized area.	Mice	Singh et al. [95]
Non-viral vectors		siRNA	~ 13 kDa	Not mentioned	VEGFA, VEGFR1 and VEGFR2	angiogenesis	subconjunctival and systemic administration of TargeTran	Subconjunctival treatment was more effective in new vessel inhibition.	Mice	Kim et al. [96]
		GFP pDNA	0.7 kb	Not mentioned	Keratocytes	POC	Topical administration of PEI-polyplexes after epithelium removal	Keratocytes were successfully transfected in the anterior and middle part of stroma.	Mice	Rodier et al. [100]
		monoclonal antibody (bevacizumab)	149 kDa	300 nm	VEGF	Neovascularization	(PEG)Albumin nanoparticles	Albumin nanoparticles and PEG-albumin nanoparticles decreased the neovascularized area by 61% and 38%, respectively.	Rats	Luis de Redín et al. [101]
Viral Vectors		monoclonal antibody (bevacizumab)	149 kDa	~ 140 nm	VEGF	Neovascularization	subconjunctivally injected mesoporous silica nanoparticles	Free and encapsulated bevacizumab led to a reduction of vascular length around 80% and 90% respectively at day 14.	Mice	Sun et al. [104]
		GFP pDNA	0.7 kb	~ 90 nm	Keratocytes	POC	Intrastromally injected adenovirus	Delivering through intrastromal injected adenoviruses led to more keratocytes transfection compared to naked pDNA.	Mice	Carlson et al. [105]
		GFP pDNA	0.7 kb	~ 22 nm	Keratocytes	POC			Mice	Lu et al. [106]

(continued on next page)

Table 1 (continued)

Bio(chemical)	Cargo	MW Cargo	Size Carrier	Target	Disease	Delivery type/ administration	Primary outcome	Tested in	Reference	
Endothelium	Naked delivery	MicroRNA	Not mentioned	~ 22 nm	hey2, gjc1, rasip1, and amot genes	Neovascularization	Topical and intrastromal administered rAAVs	Only after removal of the epithelium serotypes rAAVrh.10 and rAAVrh.39 transfected successfully.	Mice	Lu et al. [107]
		GFP pDNA	0.7 kb	~ 22 nm	Keratocytes	POC	Subconjunctival and intrastromal administered rAAV	Both administration routes resulted in a significant decrease of vascularized areas.	Mice	Hippert et al. [108]
		GFP pDNA	0.7 kb	~ 22 nm	Stromal cells	POC	Intrastromally injected AAV using micro sized needles	GFP expression remained for 17 months. Administrating an LPS or PBS injection led to a temporary boost in expression likely due to an inflammatory response to the injection.	Rabbits	Gilger et al. [110]
		Smad7 gene	1.3 kb	~ 22 nm	Stromal cells	Corneal haze formation	topical delivery of AAV5	Injections with micro sized needles were more accurate and led to less anterior chamber penetration and leakage. Treated eyes showed relatively less cloudiness and haze.	Rabbits	Gupta et al. [111]
		sFlk-1 gene	Not mentioned	~ 90 nm	Stromal cells	Neovascularization	Injection of rAV into aqueous humor	None of the treated rats developed moderate to severe angiogenesis.	Rats	Yu et al. [112]
		siRNA	~ 13 kDa	–	Adrenergic Receptor beta-2	glaucoma and intraocular pressure	Naked delivery	Results indicated a lowering of intraocular pressure in open-angle glaucoma patients, without adverse events.	Rabbits	Martínez et al. [136]
		antisense oligonucleotide	7 kDa	–	MALAT1	POC	Intravitreal and intracameral injections	A reduced expression of MALAT1 of ~60% after both intravitreal and intracameral injection could be observed.	Mice	Chau et al. [137]
		GFP pDNA	0.7 kb	~ 90 nm	Endothelial cells	POC	Intracamerally injected rAV	GFP expression after transfection could be temporarily be increased by intravitreally injecting LPS. After the inflammation subsided expression also decreased. This boost was repeatable a second time.	Rabbit	Tsai et al. [109]
		lacZ gene	3,1 kb	~ 90 nm	Endothelial cells	POC	rAV after Intracamerally or intravitreally injected	Both administration routes led to expression however injections into the aqueous humor were favorable as more mice showed expression.	Mice	Budenz et al. [132]
		lacZ gene	3,1 kb	~ 22 nm & 200 nm	Endothelial cells	POC	rAAV and rHSV while in storage medium	Only 2% of the endothelial cells were transfected in both species which lasted for 4 weeks with rAAV compared to 5% transfection for a week using rHSV.	Ex vivo (Rabbit & human)	Hudde et al. [139]
GFP pDNA	0.7 kb	~ 22 nm	Endothelial cells	POC	rAAV2 onto ex vivo endothelial layer	Transfection levels of 90% for two weeks could be achieved using an rAAV2 vector.	Ex vivo (human)	Lai et al. [140]		
GFP pDNA	0.7 kb	~ 90 nm	Endothelial cells	POC	Lentivirus with intracameral injection	Expression of GFP across most of the corneal diameter could be achieved which lasted at least for 12 weeks.	Mice	Bainbridge et al. [135]		
Physical	Cargo	Size Cargo	Size Carrier	Target	Disease	Delivery type/ administration	Primary outcome	Tested in	Reference	
Epithelium	Electroporation	luciferase pDNA	5,8 kb	–	Epithelial cells	POC	Electroporation after subconjunctival or intrastromal injection	Using a subconjunctival injection led to a higher expression but declined faster compared to an intrastromal injection.	Mice	Blair-Parks et al. [82]
	Gene Gun	GFP pDNA	0.7 kb	2.6 μm	Epithelial cells	POC	Gene gun	Expression was only present around the gold beads. Adjusting gene gun pressure allowed to target different epithelial layers.	Rabbits	Tanelian et al. [85]
	Gene Gun	IL-10 and luciferase pDNA	Not mentioned	0.6 & 1.6 2.6 μm	Epithelial cells	POC	Gene gun		Mice	Zhang et al. [86]

(continued on next page)

Table 1 (continued)

Physical	Cargo	Size Cargo	Size Carrier	Target	Disease	Delivery type/ administration	Primary outcome	Tested in	Reference	
<b>Stroma</b>	IL-4 and IL-10 pDNA	Not mentioned	0.6 & 1.6 2.6 µm	Epithelial cells	herpetic stromal keratitis	Gene gun	Adjusting distance and pressure of the gene gun led to IL-10 and luciferase expression while minimizing side effects. IL-10 and IL-4 pDNA could successfully delivered and led to increased IL-10 and IL-4 concentrations.	Mice	Bauer et al. [87]	
	K12 promoter-β-gal DNA	2,5 kb	0.6 & 1.6 2.6 µm	Epithelial cells	Promotor identification	Gene gun	Expression was visible in corneal epithelium but not conjunctiva. Indicating K12 was located in the epithelium.	Rabbits	Shiraishi et al. [88]	
	Sonoporation	GFP pDNA	0.7 kb	–	Keratocytes	POC	Sonoporation	The transfected cells displayed increasing GFP expression for 8 days which slowly decreased and disappeared completely 30 days after treatment.	Rabbits	Sonoda et al. [116]
	Electroporation	luciferase pDNA	5,8 kb	–	Keratocytes	POC	Electroporation after intracorneal injection Electroporation	Luciferase expression could successfully be detected 7 days after the treatment.	Mice	Blair-Parks et al. [82]
		GFP pDNA	0.7 kb	–	Keratocytes	POC		Using 20 V pulses (50 ms) for GFP pDNA delivery led to GFP expression without apparent damage. 40 V pulses led to neovascularization.	Rats	Oshima et al. [117]
<b>Endothelium</b>	Microneedles	monoclonal antibody (bevacizumab)	149 kDa	–	VEGF	Neovascularization	Coated microneedles	Microneedles and traditional injection led to a similar reduction of neovascularization. However only a 550 times lower dose was needed for the microneedles.	Rabbits	Kim et al. [118]
	Light based delivery	monoclonal antibody (DC101)	150 kDa	–	VEGFR2	Neovascularization	Microneedles with fast dissolving diclofenac core and DC101 loaded slow release outer shell	Treatment led to a vascularized area of only 0.16 mm <sup>2</sup> while diclofenac only and DC101 only resulted in a vascularized area of 0.63 mm <sup>2</sup> and 0.52 mm <sup>2</sup> respectively.	Mice	Than et al. [119]
		GFP pDNA	0.7 kb	–	Keratocytes	POC	Laser created pocket followed by an injection with lentiviral vector	Injecting lentivirus vectors expressing GFP in through light based created pockets led to a transduction of 90% surrounding the pocket.	Ex vivo (porcine)	Bemelmans et al. [131]
Electroporation	tPA DNA	1,7 kb	–	Endothelial cells	Intracameral Fibrin Formation	Electroporation after injection into the anterior chamber	Active tPA was clearly present for 4 days after treatment lowering corneal opacity.	Rats	Sakamoto et al. [142]	
	lacZ pDNA	3,1 kb	–	Endothelial cells	POC	Electroporation after injection of naked pDNA into aqueous humor	20 V (50 ms) pulses showed successful gene transfection without apparent damage. 40 V or higher led to corneal opacity after 3 days.	Rats	Oshima et al. [144]	
	Gene Gun	lacZ pDNA	3,1 kb	Not mentioned	Endothelial cells	POC	Gene gun	Directly targeting the endothelial led to irreversibly damaging the endothelial cells.	Ex vivo (Ovine)	Klebe et al. [144]

[152]) to be delivered directly into the region of interest. It is suggested that the local dissolution of solid (coated) needles leads to much higher localized concentrations than when using regular injections, thus a lower dosage might be sufficient. Also, mesoporous silica nanoparticles slowly releasing proteins are also attractive as it decreases the amount of injections needed in a treatment schedule [104].

It is also important not to lose sight of patient comfort. In all the above studies, most of the observed effects last a couple of weeks, at most, which means multiple injections would be necessary, thus lowering patient compliance. Besides, invasive treatments by injection can lead to infections adding an extra risk [153]. While topical administration would be most ideal, it still seems today that subconjunctival or intrastromal injections are the most efficient ways to administer drugs to the cornea. However, recently, quantum dots have been shown to reach the stroma after topical administration and exert an antibiotic activity against *Staphylococcus aureus* [154]; the authors suggested the investigated quantum dots disrupt epithelial tight junctions [155,155]. Such rather unexpected observations might stimulate the drug delivery community to find approaches which make topical delivery biologics into the cornea true.

## 7. Conclusion

This review summarized various strategies to deliver biologics to the cornea. Examples with varying success in transfecting the different layers of the cornea are reported. However, to us many studies remain rather observational: while the extent of delivery of biological molecules is reported (using ex vivo or in vivo models), the biological barriers that are limiting the delivery process are mostly not investigated in detail and remain thus largely unclear. Indeed, it undoubtedly appears that fundamental studies to obtain much better insights into interactions between biologics and the corneal layers are highly needed. Moreover, in animal studies showing successful delivery of biologics in the cornea, details on the distribution, degradation and clearance of biologics is often lacking. It is also important to mention that efficient approaches to deliver biologics in the cornea might open new perspectives as well for optimizing corneal storage and therefore improving the quality of corneal grafts. Though there is still a long way to go, research on the corneal delivery of biologics holds great promise and comprehensive studies will certainly allow to bridge the gap towards clinical translation.

## Conflicts of interest

None.

## References

- [1] WHO, Global Data on Visual Impairments 2010. <http://www.who.int/blindness/GLOBALDATAFINALforweb.pdf>, 2012 (accessed August 15, 2017).
- [2] M. Sacchetti, A. Lambiase, Diagnosis and management of neurotrophic keratitis, *Clin. Ophthalmol.* 8 (2014) 571–579, <https://doi.org/10.2147/OPHT.S45921>.
- [3] Y. Bu, K.C. Shih, S.S. Kwok, Y.K. Chan, A.C.-Y. Lo, T.C.Y. Chan, V. Jhanji, L. Tong, Experimental modeling of cornea wound healing in diabetes: clinical applications and beyond, *BMJ Open Diabetes Res. Care* 7 (2019), <https://doi.org/10.1136/BMJDR-2019-000779>.
- [4] S.R. Nyman, M.A. Gosney, C.R. Victor, Emotional well-being in people with sight loss, *Br. J. Vis. Impair.* 28 (2010) 175–203, <https://doi.org/10.1177/0264619610374171>.
- [5] V. Tadić, A.O. Robertson, M. Cortina-Borja, J.S. Rahi, Child vision patient-reported outcome measures group, an age- and stage-appropriate patient-reported outcome measure of vision-related quality of life of children and young people with visual impairment, *Ophthalmology* 127 (2020) 249–260, <https://doi.org/10.1016/j.ophtha.2019.08.033>.
- [6] P. Gain, R. Julienne, Z. He, M. Aldossary, S. Acquart, F. Cognasse, G. Thuret, Global survey of corneal transplantation and eye banking, *JAMA Ophthalmol.* 134 (2016) 167, <https://doi.org/10.1001/jamaophthalmol.2015.4776>.
- [7] K.H. Wong, K.W. Kam, L.J. Chen, A.L. Young, Corneal blindness and current major treatment concern-graft scarcity, *Int. J. Ophthalmol.* 10 (2017) 1154, <https://doi.org/10.18240/IJO.2017.07.21>.
- [8] B. Zhang, Q. Xue, J. Li, L. Ma, Y. Yao, H. Ye, Z. Cui, H. Yang, 3D bioprinting for artificial cornea: challenges and perspectives, *Med. Eng. Phys.* 71 (2019) 68–78, <https://doi.org/10.1016/j.MEDENGPHY.2019.05.002>.
- [9] L. Lin, X. Jin, The development of tissue engineering corneal scaffold: which one the history will choose? *Ann. Eye Sci.* 3 (2018) 1–8, <https://doi.org/10.21037/aes.2018.01.01>.
- [10] A.C. Anselmo, Y. Gokarn, S. Mitragotri, Non-invasive delivery strategies for biologics, *Nat. Rev. Drug Discov.* 18 (2019) 19–40, <https://doi.org/10.1038/nrd.2018.183>.
- [11] J.S. Weiss, H.U. Möller, W. Lisch, S. Kinoshita, A.J. Aldave, M.W. Belin, T. Kivelä, M. Busin, F.L. Munier, B. Seitz, J. Sutphin, C. Bredrup, M.J. Mannis, C.J. Rapuano, G. Van Rij, E.K. Kim, G.K. Klintworth, The IC3D classification of the corneal dystrophies, *Cornea* 27 (Suppl. 2) (2008) S1–83, <https://doi.org/10.1097/ICO.0b013e31817780fb>.
- [12] V. Oliver, K. van Bysterveldt, M. Cadzow, B. Steger, V. Romano, D. Markie, A. Hewitt, D. Mackey, C. Willoughby, T. Sherwin, P. Crosier, C. McGhee, A. Vincent, A COL17A1 splice-altering mutation is prevalent in inherited recurrent corneal erosions, *Ophthalmology* 123 (2016), <https://doi.org/10.1016/j.OPTH.2015.12.008>.
- [13] M.E. Fini, B.M. Stramer, How the cornea heals: cornea-specific repair mechanisms affecting surgical outcomes, *Cornea* 24 (2005), <https://doi.org/10.1097/01.ICO.0000178743.06340.2C>.
- [14] R.R. Mohan, Corneal transparency restoration by gene therapy, *Acta Ophthalmol.* 97 (2019), <https://doi.org/10.1111/j.1755-3768.2019.8248.j.1755-3768.2019.8248>.
- [15] M.D.P. Willcox, P. Argüeso, G.A. Georgiev, J.M. Holopainen, G.W. Laurie, T. J. Millar, E.B. Papas, J.P. Rolland, T.A. Schmidt, U. Stahl, T. Suarez, L. Subbaraman, O.Ö. Uçakhan, L. Jones, TFOS DEWS II tear film report, *Ocul. Surf.* 15 (2017) 366–403, <https://doi.org/10.1016/j.JTOS.2017.03.006>.
- [16] S. Mishima, A. Gasset, S.D. Klyce, J.L. Baum, Determination of tear volume and tear flow, *Invest. Ophthalmol. Vis. Sci.* 5 (1966) 264–276. <https://iovs.arvojournals.org/article.aspx?articleid=2203634> (accessed June 24, 2020).
- [17] S.-C. Chang, V.H.L. Lee, Nasal and conjunctival contributions to the systemic absorption of topical timolol in the pigmented rabbit: implications in the design of strategies to maximize the ratio of ocular to systemic absorption, *J. Ocul. Pharmacol. Ther.* 3 (1987) 159–169, <https://doi.org/10.1089/jop.1987.3.159>.
- [18] A. Urtti, H. Rouhiainen, T. Kaila, V. Saano, Controlled ocular timolol delivery: systemic absorption and intraocular pressure effects in humans, *Pharm. Res.* 11 (1994) 1278–1282, <https://doi.org/10.1023/A:1018938310628>.
- [19] L. Cwiklik, Tear film lipid layer: a molecular level view, *Biochim. Biophys. Acta Biomembr.* 1858 (2016) 2421–2430, <https://doi.org/10.1016/j.BBAMEM.2016.02.020>.
- [20] L. Sebbag, L.M. Moody, J.P. Mochel, Albumin levels in tear film modulate the bioavailability of medically-relevant topical drugs, *Front. Pharmacol.* 10 (2019) 1560, <https://doi.org/10.3389/fphar.2019.01560>.
- [21] N.J. Van Haeringen, Clinical biochemistry of tears, *Surv. Ophthalmol.* 26 (1981) 84–96, [https://doi.org/10.1016/0039-6257\(81\)90145-4](https://doi.org/10.1016/0039-6257(81)90145-4).
- [22] Y. Danjo, L.D. Hazlett, I.K. Gipson, C57BL/6 mice lacking Muc1 show no ocular surface phenotype, *Invest. Ophthalmol. Vis. Sci.* 41 (2000) 4080–4084. <https://iovs.arvojournals.org/article.aspx?articleid=2162707> (accessed June 25, 2020).
- [23] R. Kardou, R.E. Price, J. Julian, E. Lagow, S.C. Tseng, S.J. Gendler, D.D. Carson, Bacterial conjunctivitis in Muc1 null mice, *Invest. Ophthalmol. Vis. Sci.* 40 (1999) 1328–1335. <http://www.ncbi.nlm.nih.gov/pubmed/10359313> (accessed June 25, 2020).
- [24] T.D. Blalock, S.J. Spurr-Michaud, A.S. Tisdale, S.R. Heimer, M.S. Gilmore, V. Ramesh, I.K. Gipson, Functions of MUC16 in corneal epithelial cells, *Investig. Ophthalmol. Vis. Sci.* 48 (2007) 4509, <https://doi.org/10.1167/iovs.07-0430>.
- [25] P. Argüeso, A. Tisdale, S. Spurr-Michaud, M. Sumiyoshi, I.K. Gipson, Mucin characteristics of human corneal-limbal epithelial cells that exclude the rose bengal anionic dye, *Invest. Ophthalmol. Vis. Sci.* 47 (2006) 113–119, <https://doi.org/10.1167/iovs.05-0735>.
- [26] F. Mantelli, P. Argüeso, Functions of ocular surface mucins in health and disease, *Curr. Opin. Allergy Clin. Immunol.* 8 (2008) 477–483, <https://doi.org/10.1097/ACI.0b013e32830e6b04>.
- [27] M. Ruponen, A. Urtti, Undefined role of mucus as a barrier in ocular drug delivery, *Eur. J. Pharm. Biopharm.* 96 (2015) 442–446, <https://doi.org/10.1016/j.JEJPB.2015.02.032>.
- [28] A. Popov, Mucus-penetrating particles and the role of ocular mucus as a barrier to micro- and nanosuspensions, *J. Ocul. Pharmacol. Ther.* (2020), <https://doi.org/10.1089/jop.2020.0022>.
- [29] J. Leal, H.D.C. Smyth, D. Ghosh, Physicochemical properties of mucus and their impact on transmucosal drug delivery, *Int. J. Pharm.* 532 (2017) 555–572, <https://doi.org/10.1016/j.IJPHARM.2017.09.018>.
- [30] S.K. Gade, N. Shivshetty, N. Sharma, S. Bhatnagar, P. Garg, V.V.K. Venuganti, Effect of Mucoadhesive polymeric formulation on corneal permeation of Fluoroquinolones, *J. Ocul. Pharmacol. Ther.* 34 (2018) 570–578, <https://doi.org/10.1089/jop.2018.0059>.
- [31] D. Sensoy, E. Cevher, A. Sarici, M. Yilmaz, A. Ozdamar, N. Bergişadi, Bioadhesive sulfacetamide sodium microspheres: evaluation of their effectiveness in the treatment of bacterial keratitis caused by *Staphylococcus aureus* and *Pseudomonas aeruginosa* in a rabbit model, *Eur. J. Pharm. Biopharm.* 72 (2009) 487–495, <https://doi.org/10.1016/j.ejpb.2009.02.006>.
- [32] R.S. Bhatta, H. Chandasana, Y.S. Chhonker, C. Rathi, D. Kumar, K. Mitra, P. K. Shukla, Mucoadhesive nanoparticles for prolonged ocular delivery of natamycin: in vitro and pharmacokinetics studies, *Int. J. Pharm.* 432 (2012) 105–112, <https://doi.org/10.1016/j.IJPHARM.2012.04.060>.

- [33] A. Fabiano, P. Chetoni, Y. Zambito, Mucoadhesive nano-sized supramolecular assemblies for improved pre-corneal drug residence time, *Drug Dev. Ind. Pharm.* 41 (2015) 2069–2076, <https://doi.org/10.3109/03639045.2015.1066798>.
- [34] E. Ramsay, E.M. del Amo, E. Toropainen, U. Tengvall-Unadike, V.-P. Ranta, A. Urtti, M. Ruponen, Corneal and conjunctival drug permeability: systematic comparison and pharmacokinetic impact in the eye, *Eur. J. Pharm. Sci.* 119 (2018) 83–89, <https://doi.org/10.1016/j.ejps.2018.03.034>.
- [35] C.S. Nowell, F. Radtke, Corneal epithelial stem cells and their niche at a glance, *J. Cell Sci.* 130 (2017) 1021–1025, <https://doi.org/10.1242/JCS.198119>.
- [36] G. Sahay, D.Y. Alakhova, A.V. Kabanov, Endocytosis of nanomedicines, *J. Control. Release* 145 (2010) 182–195, <https://doi.org/10.1016/j.jconrel.2010.01.036>.
- [37] K.M. Association for Research in Vision and Ophthalmology, K. Kananen, S. Auriola, K. Kontturi, A. Urtti, Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera, *Invest. Ophthalmol. Vis. Sci.* 38 (1997) 627–634, <https://iovs.arvojournals.org/article.aspx?articleid=2161463> (accessed June 26, 2020).
- [38] E. Mannermaa, K.-S. Vellonen, A. Urtti, Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics, *Adv. Drug Deliv. Rev.* 58 (2006) 1136–1163, <https://doi.org/10.1016/j.addr.2006.07.024>.
- [39] J. Liaw, Y. Rojanasakul, J.R. Robinson, The effect of drug charge type and charge density on corneal transport, *Int. J. Pharm.* 88 (1992) 111–124, [https://doi.org/10.1016/0378-5173\(92\)90308-O](https://doi.org/10.1016/0378-5173(92)90308-O).
- [40] S.E. Wilson, J.W. Hong, Bowman's layer structure and function: critical or dispensable to corneal function? A hypothesis, *Cornea*. 19 (2000) 417–420, <https://doi.org/10.1097/00003226-200007000-00001>.
- [41] E.P. Holowka, S.K. Bhatia, Thin-film materials, in: *Drug Deliv*, Springer New York, New York, NY, 2014, pp. 63–116, [https://doi.org/10.1007/978-1-4939-1998-7\\_3](https://doi.org/10.1007/978-1-4939-1998-7_3).
- [42] A. Ben-Zvi, M.M. Rodrigues, J.H. Krachmer, L.S. Fujikawa, Immunohistochemical characterization of extracellular matrix in the developing human cornea, *Curr. Eye Res.* 5 (1986) 105–117, <https://doi.org/10.3109/02713688609015099>.
- [43] D.E. Birk, J.M. Fitch, J.P. Babiarz, T.F. Linsenmayer, Collagen type I and type V are present in the same fibril in the avian corneal stroma, *J. Cell Biol.* 106 (1988) 999–1008, <https://doi.org/10.1083/jcb.106.3.999>.
- [44] M.R. Prausnitz, J.S. Noonan, Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye, *J. Pharm. Sci.* 87 (1998) 1479–1488, <https://doi.org/10.1021/JS9802594>.
- [45] U. Labermeier, T.A. Demlow, M.C. Kenney, Identification of collagens isolated from bovine Descemet's membrane, *Exp. Eye Res.* 37 (1983) 225–237, [https://doi.org/10.1016/0014-4835\(83\)90157-4](https://doi.org/10.1016/0014-4835(83)90157-4).
- [46] W. Ishizaki, M. Westerhausen-Larson, A. Kino, J. Hayashi, T. Kao, Distribution of collagen IV in human ocular tissues, *Invest. Ophthalmol. Vis. Sci.* 34 (1993) 2680–2689, <https://iovs.arvojournals.org/article.aspx?articleid=2160867> (accessed June 27, 2020).
- [47] J.A. Last, S.J. Liliensiek, P.F. Nealey, C.J. Murphy, Determining the mechanical properties of human corneal basement membranes with atomic force microscopy, *J. Struct. Biol.* 167 (2009) 19–24, <https://doi.org/10.1016/j.jsb.2009.03.012>.
- [48] M. Fannon, K. Forsten-Williams, B. Zhao, E. Bach, P.P. Parekh, C.L. Chu, A. L. Georges-Wildt, J.A. Buczek-Thomas, M.A. Nugent, Facilitated diffusion of VEGF165 through descemet's membrane with sucrose octasulfate, *J. Cell. Physiol.* 227 (2012) 3693–3700, <https://doi.org/10.1002/jcp.24077>.
- [49] V. Beaulieu Leclerc, O. Roy, K. Santerre, S. Proulx, TGF- $\beta$ 1 promotes cell barrier function upon maturation of corneal endothelial cells, *Sci. Rep.* 8 (2018) 4438, <https://doi.org/10.1038/s41598-018-22821-9>.
- [50] K.J. Mandell, G.P. Holley, C.A. Parks, H.F. Edelhauser, Antibody blockade of Junctional adhesion molecule-A in rabbit corneal endothelial tight junctions produces corneal swelling, *Investig. Ophthalmol. Vis. Sci.* 47 (2006) 2408, <https://doi.org/10.1167/iovs.05-0745>.
- [51] M. Durymanov, J. Reineke, Non-viral delivery of nucleic acids: insight into mechanisms of overcoming intracellular barriers, *Front. Pharmacol.* 9 (2018) 971, <https://doi.org/10.3389/fphar.2018.00971>.
- [52] G.A. de Souza, L.M. Godoy, M. Mann, Identification of 491 proteins in the tear fluid proteome reveals a large number of proteases and protease inhibitors, *Genome Biol.* 7 (2006) R72, <https://doi.org/10.1186/GB-2006-7-8-R72>.
- [53] T.N. Yusifov, A.R. Abduragimov, K. Narsinh, O.K. Gasymov, B.J. Glasgow, Tear lipocalin is the major endonuclease in tears, *Mol. Vis.* 14 (2008) 180, <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2254967/> (accessed July 20, 2020).
- [54] H. Yin, R.L. Kanasty, A.A. Eltoukhy, A.J. Vegas, J.R. Dorkin, D.G. Anderson, Non-viral vectors for gene-based therapy, *Nat. Rev. Genet.* 15 (2014) 541–555, <https://doi.org/10.1038/nrg3763>.
- [55] C. Cursiefen, E. Viaud, F. Bock, B. Geudelin, A. Ferry, P. Kadlecová, M. Lévy, S. Al Mahmood, S. Colin, E. Thorin, F. Majo, B. Frueh, F. Wilhelm, T. Meyer-Ter-Vehn, G. Geerling, D. Böhringer, T. Reinhard, D. Meller, U. Pleyer, B. Bachmann, B. Seitz, Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: the I-CAN study, *Ophthalmology*. 121 (2014) 1683–1692, <https://doi.org/10.1016/j.ophttha.2014.03.038>.
- [56] J.M. Benitez-Del-Castillo, J. Moreno-Montañés, I. Jiménez-Alfaro, F.J. Muñoz-Negrete, K. Turman, K. Palumaa, B. Sádaba, M.V. González, V. Ruz, B. Vargas, C. Paneda, T. Martínez, A.-M. Bleau, A.I. Jimenez, Safety and efficacy clinical trials for SYL1001, a novel short interfering RNA for the treatment of dry eye disease, *Investig. Ophthalmol. Vis. Sci.* 57 (2016) 6447, <https://doi.org/10.1167/iovs.16-20303>.
- [57] V. Gonzalez, V. Ruz, A.M. Bleau, B. Vargas, A.I. Jimenez, Tivanisiran as a new treatment for dry eye in patients with Sjögren syndrome, *Invest. Ophthalmol. Vis. Sci.* 61 (2020) 102, <https://iovs.arvojournals.org/article.aspx?articleid=2769224>.
- [58] I. Ruseska, A. Zimmer, Internalization mechanisms of cell-penetrating peptides, *Beilstein J. Nanotechnol.* 11 (2020) 101–123, <https://doi.org/10.3762/bjnano.11.10>.
- [59] L.N. Johnson, S.M. Cashman, R. Kumar-Singh, Cell-penetrating peptide for enhanced delivery of nucleic acids and drugs to ocular tissues including retina and cornea, *Mol. Ther.* 16 (2008) 107–114, <https://doi.org/10.1038/SJ.MT.6300324>.
- [60] L.N. Johnson, S.M. Cashman, S.P. Read, R. Kumar-Singh, Cell penetrating peptide POD mediates delivery of recombinant proteins to retina, cornea and skin, *Vis. Res.* 50 (2010) 686–697, <https://doi.org/10.1016/j.visres.2009.08.028>.
- [61] F. Joris, L. De Backer, T. Van de Vyver, C. Bastiancich, S.C. De Smedt, K. Raemdonck, Repurposing cationic amphiphilic drugs as adjuvants to induce lysosomal siRNA escape in nanogel transfected cells, *J. Control. Release* 269 (2018) 266–276, <https://doi.org/10.1016/j.jconrel.2017.11.019>.
- [62] T. Van de Vyver, B. Bogaert, L. De Backer, F. Joris, R. Guagliardo, J. Van Hoeck, P. Merckx, S. Van Calenbergh, S. Ramishetti, D. Peer, K. Remaut, S.C. De Smedt, K. Raemdonck, Cationic amphiphilic drugs boost the lysosomal escape of small nucleic acid therapeutics in a nanocarrier-dependent manner, *ACS Nano* 14 (2020) 4774–4791, <https://doi.org/10.1021/acsnano.0c00666>.
- [63] F. Joris, S.C. De Smedt, K. Raemdonck, Small molecules convey big messages: boosting non-viral nucleic acid delivery with low molecular weight drugs, *Nano Today* 16 (2017) 14–29, <https://doi.org/10.1016/J.NANTOD.2017.06.012>.
- [64] D. Schirotti, M.J. Gómara, E. Maurizi, S.D. Atkinson, L. Mairs, K.A. Christie, D. F. Cobice, C.M. McCrudden, M.A. Nesbit, I. Haro, T. Moore, Effective in vivo topical delivery of siRNA and gene silencing in intact corneal epithelium using a modified cell-penetrating peptide, *Mol. Ther.* - Nucleic Acids. 17 (2019) 891–906, <https://doi.org/10.1016/J.OMTN.2019.07.017>.
- [65] H.N. Bernstein, Chloroquine ocular toxicity, *Surv. Ophthalmol.* 12 (1967) 415–447.
- [66] F. Zahir-Jouzani, M. Soleimani, M. Mahbod, F. Mottaghtalab, F. Vakhshite, E. Arefian, S. Shahhoseini, R. Dinarvand, F. Atayabi, Corneal chemical burn treatment through a delivery system consisting of TGF- $\beta$ 1 siRNA: in vitro and in vivo, *Drug Deliv. Transl. Res.* 8 (2018) 1127–1138, <https://doi.org/10.1007/s13346-018-0546-0>.
- [67] M. Goel, R.G. Picciani, R.K. Lee, S.K. Bhattacharya, Aqueous humor dynamics: a review, *Open Ophthalmol. J.* 4 (2010) 52–59, <https://doi.org/10.2174/1874364101004010052>.
- [68] W. Yuan, H. Li, Polymer-based nanocarriers for therapeutic nucleic acids delivery, *Nanostruct. Drug Deliv.* (2017) 445–460, <https://doi.org/10.1016/B978-0-323-46143-6.00014-2>.
- [69] P. Baran-Rachwalska, N. Torabi-Pour, F.M. Sutura, M. Ahmed, K. Thomas, M. A. Nesbit, M. Welsh, C.B.T. Moore, S.R. Saffie-Siebert, Topical siRNA delivery to the cornea and anterior eye by hybrid silicon-lipid nanoparticles, *J. Control. Release* 326 (2020) 192–202, <https://doi.org/10.1016/J.JCONREL.2020.07.004>.
- [70] D. Bouard, D. Alazard-Dany, F.-L. Cosset, Viral vectors: from virology to transgene expression, *Br. J. Pharmacol.* 157 (2009) 153–165, <https://doi.org/10.1038/bjp.2008.349>.
- [71] US Food and Drug Administration, FDA Approves Novel Gene Therapy to Treat Patients with a Rare Form of Inherited Vision Loss | FDA, <https://www.fda.gov/news-events/press-announcements/fda-approves-novel-gene-therapy-treat-patients-rare-form-inherited-vision-loss>, 2017.
- [72] S.M. Hoy, Onasemnogene Apeparovet: First Global Approval, *Drugs*. 79 (2019) 1255–1262, <https://doi.org/10.1007/s40265-019-01162-5>.
- [73] G. Karponi, N. Zogas, gene therapy for beta-thalassemia: updated perspectives, *Appl. Clin. Genet.* 12 (2019) 167–180, <https://doi.org/10.2147/TACG.S178546>.
- [74] C.A. Challenger, Seeking solutions for large-scale GMP viral vector manufacturing, *Pharm. Technol.* 43 (2019) 22–26.
- [75] K. Tsubota, H. Inoue, K. Ando, M. Ono, K. Yoshino, I. Saito, Adenovirus-mediated gene transfer to the ocular surface epithelium, *Exp. Eye Res.* 67 (1998) 531–538, <https://doi.org/10.1006/EXER.1998.0557>.
- [76] I.-J. Wang, M.-C. Jhuang, Y.-H. Chen, L.-K. Yeh, C.-Y. Liu, T.-H. Young, Chitosan modification of adenovirus to modify transfection efficiency in bovine corneal epithelial cells, *PLoS One* 5 (2010), e12085, <https://doi.org/10.1371/journal.pone.0012085>.
- [77] B. Spencer, S. Agarwala, M. Miskulin, M. Smith, C.R. Brandt, Herpes simplex virus-mediated gene delivery to the rodent visual system, *Invest. Ophthalmol. Vis. Sci.* 41 (2000) 1392–1401.
- [78] M. Silva, R. Calado, J. Marto, A. Bettencourt, A. Almeida, L. Gonçalves, Chitosan nanoparticles as a mucoadhesive drug delivery system for ocular administration, *Mar. Drugs*. 15 (2017) 370, <https://doi.org/10.3390/md15120370>.
- [79] W. Chaiyasan, S.P. Srinivas, W. Tiyaboonchai, Mucoadhesive chitosan-dextran sulfate nanoparticles for sustained drug delivery to the ocular surface, *J. Ocul. Pharmacol. Ther.* 29 (2013) 200–207, <https://doi.org/10.1089/jop.2012.0193>.
- [80] E. Sokotowska, A.U. Blachnio-Zabielska, A critical review of electroporation as a plasmid delivery system in mouse skeletal muscle, *Int. J. Mol. Sci.* 20 (2019), <https://doi.org/10.3390/IJMS20112776>.
- [81] J. Shi, Y. Ma, J. Zhu, Y. Chen, Y. Sun, Y. Yao, Z. Yang, J. Xie, A Review on electroporation-based intracellular delivery, *Molecules*. 23 (2018), <https://doi.org/10.3390/MOLECULES23113044>.
- [82] K. Blair-Parks, B.C. Weston, D.A. Dean, High-level gene transfer to the cornea using electroporation, *J. Gene Med.* 4 (2002) 92–100, <https://doi.org/10.1002/jgm.231>.

- [83] R. Zhou, D.A. Dean, Gene transfer of interleukin 10 to the murine cornea using electroporation, *Exp. Biol. Med.* 232 (2007) 362–369, <https://doi.org/10.3181/00379727-232-2320362>.
- [84] M.T.S. Lin, L. Pulkkinen, J. Uitto, K. Yoon, The gene gun: current applications in cutaneous gene therapy, *Int. J. Dermatol.* 39 (2000) 161–170, <https://doi.org/10.1046/j.1365-4362.2000.00925.x>.
- [85] D.L. Tanelian, M.A. Barry, S.A. Johnston, T. Le, G. Smith, Controlled gene gun delivery and expression of DNA within the cornea, *Biotechniques*. 23 (1997) 484–488, <https://doi.org/10.2144/97233st06>.
- [86] E.-P. Zhang, A. Müller, F. Schulte, S.A. König, M. Merediz, F. Sack, C. Junghans, B. Wittig, F. Hoffmann, Minimizing side effects of ballistic gene transfer into the murine corneal epithelium, *Graefes Arch. Clin. Exp. Ophthalmol.* 240 (2002) 114–119, <https://doi.org/10.1007/s00417-001-0411-5>.
- [87] D. Bauer, M. Lu, S. Wasmuth, H. Li, Y. Yang, M. Roggendorf, K.P. Steuhl, A. Heiligenhaus, Immunomodulation by topical particle-mediated administration of cytokine plasmid DNA suppresses herpetic stromal keratitis without impairment of antiviral defense, *Graefes Arch. Clin. Exp. Ophthalmol.* 244 (2006) 216–225, <https://doi.org/10.1007/s00417-005-0070-z>.
- [88] A. Shirraishi, R.L. Converse, C.Y. Liu, F. Zhou, C.W. Kao, W.W. Kao, Identification of the cornea-specific keratin 12 promoter by in vivo particle-mediated gene transfer, *Invest. Ophthalmol. Vis. Sci.* 39 (1998) 2554–2561, <https://iovs.arvojournals.org/article.aspx?articleid=2161680> (accessed July 2, 2020).
- [89] I.S. Zagon, J.W. Sassani, K.J. Malefyt, P.J. McLaughlin, Regulation of corneal repair by particle-mediated gene transfer of opioid growth factor receptor complementary DNA, *Arch. Ophthalmol.* 124 (2006) 1620, <https://doi.org/10.1001/archoph.124.11.1620>.
- [90] B. D. W. S. L. M. H. A. Particle-mediated administration of plasmid DNA on corneas of BALB/c mice, *Methods Mol. Biol.* 940 (2013), [https://doi.org/10.1007/978-1-62703-110-3\\_18](https://doi.org/10.1007/978-1-62703-110-3_18).
- [91] W.T. Godbey, W.T. Godbey, Gene Delivery, An Introd. to Biotechnol, 2014, pp. 275–312, <https://doi.org/10.1016/B978-1-907568-28-2.00013-7>.
- [92] N.S. Abdelfattah, M. Amgad, A.A. Zayed, H. Salem, A.E. Elkhanany, H. Hussein, N. Abd El-Baky, Clinical correlates of common corneal neovascular diseases: a literature review, *Int. J. Ophthalmol.* 8 (2015) 182–193, <https://doi.org/10.3980/j.issn.2222-3959.2015.01.32>.
- [93] W. Philipp, L. Speicher, C. Humpel, Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas, *Invest. Ophthalmol. Vis. Sci.* 41 (2000) 2514–2522, <http://www.ncbi.nlm.nih.gov/pubmed/10937562> (accessed August 9, 2020).
- [94] L. Zuo, Y. Fan, F. Wang, Q. Gu, X. Xu, A siRNA targeting vascular endothelial growth factor-a inhibiting experimental corneal neovascularization, *Curr. Eye Res.* 35 (2010) 375–384, <https://doi.org/10.3109/02713681003597230>.
- [95] N. Singh, E. Higgins, S. Amin, P. Jani, E. Richter, A. Patel, R. Kaur, J. Wang, J. Ambati, Z. Dong, B.K. Ambati, Unique homologous siRNA blocks hypoxia-induced VEGF upregulation in human corneal cells and inhibits and regresses murine corneal neovascularization, *Cornea*. 26 (2007) 65–72, <https://doi.org/10.1097/ICO.0b013e31802b4201>.
- [96] B. Kim, Q. Tang, P.S. Biswas, J. Xu, R.M. Schiffelers, F.Y. Xie, A.M. Ansari, P. V. Scaria, M.C. Woodle, P. Lu, B.T. Rouse, Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis, *Am. J. Pathol.* 165 (2004) 2177–2185, [https://doi.org/10.1016/S0002-9440\(10\)63267-1](https://doi.org/10.1016/S0002-9440(10)63267-1).
- [97] E.A. Azzopardi, E.L. Ferguson, D.W. Thomas, The enhanced permeability retention effect: a new paradigm for drug targeting in infection, *J. Antimicrob. Chemother.* 68 (2013) 257–274, <https://doi.org/10.1093/jac/dks379>.
- [98] S.K. Golombek, J.-N. May, B. Theek, L. Appold, N. Drude, F. Kiessling, T. Lammers, Tumor targeting via EPR: strategies to enhance patient responses, *Adv. Drug Deliv. Rev.* 130 (2018) 17–38, <https://doi.org/10.1016/j.addr.2018.07.007>.
- [99] R.M. Schiffelers, G. Storm, ICS-283: a system for targeted intravenous delivery of siRNA, *Expert Opin. Drug Deliv.* 3 (2006) 445–454, <https://doi.org/10.1517/17425247.3.3.445>.
- [100] J.T. Rodier, R. Tripathi, M.K. Fink, A. Sharma, M. Korampally, S. Gangopadhyay, E.A. Giuliano, P.R. Sinha, R.R. Mohan, Linear polyethylenimine-DNA nanoconstruct for corneal gene delivery, *J. Ocul. Pharmacol. Ther.* 35 (2019) 23–31, <https://doi.org/10.1089/jop.2018.0024>.
- [101] I. Luis de Redín, C. Boiero, S. Recalde, M. Agüeros, D. Allemandi, J.M. Llabot, A. García-Layana, J.M. Irache, In vivo effect of bevacizumab-loaded albumin nanoparticles in the treatment of corneal neovascularization, *Exp. Eye Res.* 185 (2019) 107697, <https://doi.org/10.1016/j.exer.2019.107697>.
- [102] S. Grisanti, F. Ziemssen, Bevacizumab: off-label use in ophthalmology, *Indian J. Ophthalmol.* 55 (2007) 417–420, <https://doi.org/10.4103/0301-4738.36474>.
- [103] T. Bro, M. Derebecka, Ø.K. Jørstad, A. Grzybowski, Off-label use of bevacizumab for wet age-related macular degeneration in Europe, *Graefes Arch. Clin. Exp. Ophthalmol.* 258 (2020) 503–511, <https://doi.org/10.1007/s00417-019-04569-8>.
- [104] J.-G. Sun, Q. Jiang, X.-P. Zhang, K. Shan, B.-H. Liu, C. Zhao, B. Yan, Mesoporous silica nanoparticles as a delivery system for improving antiangiogenic therapy, *Int. J. Nanomedicine* 14 (2019) 1489–1501, <https://doi.org/10.2147/IJN.S195504>.
- [105] E.C. Carlson, C.-Y. Liu, X. Yang, M. Gregory, B. Ksander, J. Drazba, V.L. Perez, In vivo gene delivery and visualization of corneal stromal cells using an adenoviral vector and Keratocyte-specific promoter, *Investig. Ophthalmol. Vis. Sci.* 45 (2004) 2194, <https://doi.org/10.1167/iovs.03-1224>.
- [106] Y. Lu, J. Ai, D. Gessler, Q. Su, K. Tran, Q. Zheng, X. Xu, G. Gao, Efficient transduction of corneal stroma by adeno-associated viral serotype vectors for implications in gene therapy of corneal diseases, *Hum. Gene Ther.* 27 (2016) 598–608, <https://doi.org/10.1089/hum.2015.167>.
- [107] Y. Lu, P.W.L. Tai, J. Ai, D.J. Gessler, Q. Su, X. Yao, Q. Zheng, P.D. Zamore, X. Xu, G. Gao, Transcriptome profiling of neovascularized corneas reveals miR-204 as a multi-target biotherapy deliverable by rAAVs, *Mol. Ther. - Nucleic Acids*. 10 (2018) 349–360, <https://doi.org/10.1016/j.omtn.2017.12.019>.
- [108] C. Hippert, S. Ibanes, N. Serratrice, F. Court, F. Malecaze, E.J. Kremer, V. Kalatzis, Corneal transduction by intra-stromal injection of AAV vectors in vivo in the mouse and ex vivo in human explants, *PLoS One* 7 (2012), e35318, <https://doi.org/10.1371/journal.pone.0035318>.
- [109] M.-L. Tsai, S.-L. Chen, P.-I. Chou, L.-Y. Wen, R.J.-F. Tsai, Y.-P. Tsao, Inducible adeno-associated virus vector-delivered transgene expression in corneal endothelium, *Invest. Ophthalmol. Vis. Sci.* 43 (2002) 751–757.
- [110] B.C. Gilger, E. Crabtree, L. Song, T. Llanga, M. Cullen, A. Blanchard, J. Salmon, S. Patel, V. Zarnitsyn, M. Hirsch, A fixed-depth microneedle enhances reproducibility and safety for corneal gene therapy, *Cornea*. 39 (2020) 362–369, <https://doi.org/10.1097/ICO.0000000000002182>.
- [111] S. Gupta, J.T. Rodier, A. Sharma, E.A. Giuliano, P.R. Sinha, N.P. Hesemann, A. Ghosh, R.R. Mohan, Targeted AAV5-Smad7 gene therapy inhibits corneal scarring in vivo, *PLoS One* 12 (2017), e0172928, <https://doi.org/10.1371/JOURNAL.PONE.0172928>.
- [112] H. Yu, J. Wu, H. Li, Z. Wang, X. Chen, Y. Tian, M. Yi, X. Ji, J. Ma, Q. Huang, Inhibition of corneal neovascularization by recombinant adenovirus-mediated sFlk-1 expression, *Biochem. Biophys. Res. Commun.* 361 (2007) 946–952, <https://doi.org/10.1016/j.bbrc.2007.07.114>.
- [113] I. Lentacker, I. De Cock, R. Deckers, S.C. De Smedt, C.T.W. Moonen, Understanding ultrasound induced sonoporation: definitions and underlying mechanisms, *Adv. Drug Deliv. Rev.* 72 (2014) 49–64, <https://doi.org/10.1016/j.addr.2013.11.008>.
- [114] S. Roovers, T. Segers, G. Lajoinie, J. Deprez, M. Versluis, S.C. De Smedt, I. Lentacker, The role of ultrasound-driven microbubble dynamics in drug delivery: from microbubble fundamentals to clinical translation, *Langmuir*. 35 (2019) 10173–10191, <https://doi.org/10.1021/acs.langmuir.8b03779>.
- [115] S. Sirsi, M. Borden, Microbubble compositions, properties and biomedical applications, *Bubble Sci. Eng. Technol.* 1 (2009) 3–17, <https://doi.org/10.1179/175889709X446507>.
- [116] S. Sonoda, K. Tachibana, E. Uchino, A. Okubo, M. Yamamoto, K. Sakoda, T. Hisatomi, K.-H. Sonoda, Y. Negishi, Y. Izumi, S. Takao, T. Sakamoto, Gene transfer to corneal epithelium and keratocytes mediated by ultrasound with microbubbles, *Investig. Ophthalmol. Vis. Sci.* 47 (2006) 558, <https://doi.org/10.1167/iovs.05-0889>.
- [117] Y. Oshima, T. Sakamoto, T. Hisatomi, C. Tsutsumi, Y. Sassa, T. Ishibashi, H. Inomata, Targeted gene transfer to corneal stroma in vivo by electric pulses, *Exp. Eye Res.* 74 (2002) 191–198, <https://doi.org/10.1006/EXER.2001.1117>.
- [118] Y.C. Kim, H.E. Grossniklaus, H.F. Edelhauser, M.R. Prausnitz, Intrastromal delivery of bevacizumab using microbubbles to treat corneal neovascularization, *Investig. Ophthalmol. Vis. Sci.* 55 (2014) 7376, <https://doi.org/10.1167/iovs.14-15257>.
- [119] A. Than, C. Liu, H. Chang, P.K. Duong, C.M.G. Cheung, C. Xu, X. Wang, P. Chen, Self-implantable double-layered micro-drug-reservoirs for efficient and controlled oral drug delivery, *Nat. Commun.* 9 (2018) 4433, <https://doi.org/10.1038/s41467-018-06981-w>.
- [120] H. Sun, M. Han, M.H. Niemz, J.F. Bille, Femtosecond laser corneal ablation threshold: dependence on tissue depth and laser pulse width, *Lasers Surg. Med.* 39 (2007) 654–658, <https://doi.org/10.1002/lsm.20538>.
- [121] H.W. Roberts, A.C. Day, D.P. O'Brart, Femtosecond laser-assisted cataract surgery: a review, *Eur. J. Ophthalmol.* 30 (2020) 417–429, <https://doi.org/10.1177/1120672119893291>.
- [122] L. Mastropasqua, L. Toto, A. Mastropasqua, L. Vecchiarino, R. Mastropasqua, E. Pedrotti, M. Di Nicola, Femtosecond laser versus manual clear corneal incision in cataract surgery, *J. Refract. Surg.* 30 (2014) 27–33, <https://doi.org/10.3928/1081597X-20131217-03>.
- [123] A.M. Wilson, J. Mazzaferri, É. Bergeron, S. Patskovsky, P. Marcoux-Valiquette, S. Costantino, P. Sapiéha, M. Meunier, In vivo laser-mediated retinal ganglion cell optoporation using K<sub>v</sub> 1.1 conjugated gold nanoparticles, *Nano Lett.* 18 (2018) 6981–6988, <https://doi.org/10.1021/acs.nanolett.8b02896>.
- [124] F. Sauvage, J.C. Fraire, K. Remaut, J. Sebag, K. Peynshaert, M. Harrington, F. J. Van de Velde, R. Xiong, M.-J. Tassignon, T. Brans, K. Braeckmans, S.C. De Smedt, Photoablation of human vitreous opacities by light-induced vapor Nanobubbles, *ACS Nano* 13 (2019) 8401–8416, <https://doi.org/10.1021/acsnano.9b04050>.
- [125] U.K. Tirlapur, K. König, Targeted transfection by femtosecond laser, *Nature*. 418 (2002) 290–291, <https://doi.org/10.1038/418290a>.
- [126] M. Waleed, S.-U. Hwang, J.-D. Kim, I. Shabbir, S.-M. Shin, Y.-G. Lee, Single-cell optoporation and transfection using femtosecond laser and optical tweezers, *Biomed. Opt. Express*. 4 (2013) 1533–1547, <https://doi.org/10.1364/BOE.4.001533>.
- [127] D.J. Stevenson, F.J. Gunn-Moore, P. Campbell, K. Dholakia, Single cell optical transfection, *J. R. Soc. Interface* 7 (2010) 863–871, <https://doi.org/10.1098/rsif.2009.0463>.
- [128] S. Vanstone, J.M. Stone, S.N. Gordeev, R.H. Guy, Mechanism of human nail poration by high-repetition-rate, femtosecond laser ablation, *Drug Deliv. Transl. Res.* 9 (2019) 956–967, <https://doi.org/10.1007/s13346-019-00638-x>.
- [129] H. Garvie-Cook, J.M. Stone, F. Yu, R.H. Guy, S.N. Gordeev, Femtosecond pulsed laser ablation to enhance drug delivery across the skin, *J. Biophotonics* 9 (2016) 144–154, <https://doi.org/10.1002/jbio.201500120>.

- [130] A.-P. Bemelmans, Y. Arsenijevic, F. Majo, Efficient lentiviral gene transfer into corneal stroma cells using a femtosecond laser, *Gene Ther.* 16 (2009) 933–938, <https://doi.org/10.1038/gt.2009.41>.
- [131] I.G. Pallikaris, G.D. Kymionis, A.D. Plaka, P.S. Binder, G.A. Kontadakis, K. I. Tsoulnaras, Femtosecond laser-assisted intra-corneal drug delivery, *Semin. Ophthalmol.* 30 (2015) 457–461, <https://doi.org/10.3109/08820538.2013.874482>.
- [132] A. Budenz, DL; Bennett, J; Alonso, L; Maguire, in vivo gene transfer into murine corneal endothelial and trabecular meshwork cells, *Invest. Ophthalmol. Vis. Sci.* 36 (1995) 2211–2215. <https://iovs.arvojournals.org/article.aspx?articleid=2161134> (accessed June 29, 2020).
- [133] R.J. Tsai, T.T. Sun, S.C. Tseng, Comparison of limbal and conjunctival autograft transplantation in corneal surface reconstruction in rabbits, *Ophthalmology.* 97 (1990) 446–455. <http://www.ncbi.nlm.nih.gov/pubmed/1691476> (accessed April 30, 2019).
- [134] J. Bainbridge, C. Stephens, K. Parsley, C. Demaison, A. Halfyard, A. Thrasher, R. Ali, In vivo gene transfer to the mouse eye using an HIV-based lentiviral vector; efficient long-term transduction of corneal endothelium and retinal pigment epithelium, *Gene Ther.* 8 (2001) 1665–1668, <https://doi.org/10.1038/sj.gt.3301574>.
- [135] V. Gonzales, J. Moreno-Montanes, M. Oll, K.N. Sall, K. Palumaa, H. Dubiner, K. Turman, F. Muñoz-Negrete, V. Ruz, A.I. Jimenez, Results of phase IIB SYLTAG clinical trial with bamosiran in patients with glaucoma, *Invest. Ophthalmol. Vis. Sci.* 57 (2016) 3023. <https://iovs.arvojournals.org/article.aspx?articleid=2561359> (accessed July 16, 2020).
- [136] T. Martínez, M.V. González, I. Roehl, N. Wright, C. Pañeda, A.I. Jiménez, In vitro and in vivo efficacy of SYLO40012, a novel siRNA compound for treatment of glaucoma, *Mol. Ther.* 22 (2014) 81–91, <https://doi.org/10.1038/MT.2013.216>.
- [137] V.Q. Chau, J. Hu, X. Gong, J.D. Hulleman, R.L. Ufret-Vincenty, F. Rigo, T. P. Prakash, D.R. Corey, V.V. Mootha, Delivery of antisense oligonucleotides to the cornea, *Nucleic Acid Ther.* 30 (2020) 207–214, <https://doi.org/10.1089/nat.2019.0838>.
- [138] E.J. McGlumphy, J.A. Margo, M. Haidara, C.H. Brown, C.K. Hoover, W.M. Munir, Predictive value of corneal donor demographics on endothelial cell density, *Cornea.* 37 (2018) 1159–1162, <https://doi.org/10.1097/ICO.0000000000001664>.
- [139] T. Hudde, S.A. Rayner, M. De Alwis, A.J. Thrasher, J. Smith, R.S. Coffin, A. J. George, D.F. Larkin, Adeno-associated and herpes simplex viruses as vectors for gene transfer to the corneal endothelium, *Cornea.* 19 (2000) 369–373, <https://doi.org/10.1097/00003226-200005000-00022>.
- [140] L.J. Lai, K.K. Lin, G.N. Foulks, L. Ma, X. Xiao, K.H. Chen, Highly efficient ex vivo gene delivery into human corneal endothelial cells by recombinant adeno-associated virus, *Curr. Eye Res.* 30 (2005) 213–219, <https://doi.org/10.1080/02713680590927515>.
- [141] K. Lundstrom, Viral vectors in gene therapy, *Dis. (Basel, Switzerland)* 6 (2018), <https://doi.org/10.3390/diseases6020042>.
- [142] T. Sakamoto, Y. Oshima, K. Nakagawa, T. Ishibashi, H. Inomata, K. Sueishi, Target gene transfer of tissue plasminogen activator to cornea by electric pulse inhibits intracameral fibrin formation and corneal cloudiness, *Hum. Gene Ther.* 10 (1999) 2551–2557, <https://doi.org/10.1089/10430349950016889>.
- [143] Y. Oshima, T. Sakamoto, I. Yamanaka, T. Nishi, T. Ishibashi, H. Inomata, Targeted gene transfer to corneal endothelium in vivo by electric pulse, *Gene Ther.* 5 (1998) 1347–1354, <https://doi.org/10.1038/sj.gt.3300725>.
- [144] S. Klebe, J. Stirling, K. Williams, Corneal endothelial cell nuclei are damaged after DNA transfer using a gene gun, *Clin. Exp. Ophthalmol.* 28 (2000) 58–59, <https://doi.org/10.1046/j.1442-9071.2000.00255.x>.
- [145] H. Wood, FDA approves patisiran to treat hereditary transthyretin amyloidosis, *Nat. Rev. Neurol.* 14 (2018) 570, <https://doi.org/10.1038/s41582-018-0065-0>.
- [146] K. Lundstrom, T. Boulikas, Viral and non-viral vectors in gene therapy: technology development and clinical trials, *Technol. Cancer Res. Treat.* 2 (2003) 471–486, <https://doi.org/10.1177/153303460300200513>.
- [147] Y.-P. Jia, B.-Y. Ma, X.-W. Wei, Z.-Y. Qian, The in vitro and in vivo toxicity of gold nanoparticles, *Chin. Chem. Lett.* 28 (2017) 691–702, <https://doi.org/10.1016/j.CCLET.2017.01.021>.
- [148] N. Zilony, A. Tzur-Balter, E. Segal, O. Shefi, Bombarding cancer: biolistic delivery of therapeutics using porous Si carriers, *Sci. Rep.* 3 (2013) 2499, <https://doi.org/10.1038/srep02499>.
- [149] P.-W. Lee, S.-F. Peng, C.-J. Su, F.-L. Mi, H.-L. Chen, M.-C. Wei, H.-J. Lin, H.-W. Sung, The use of biodegradable polymeric nanoparticles in combination with a low-pressure gene gun for transdermal DNA delivery, *Biomaterials.* 29 (2008) 742–751, <https://doi.org/10.1016/j.biomaterials.2007.10.034>.
- [150] B.S. Tremblay, Thermal techniques for reshaping the cornea, in: *International Society for Optics and Photonics*, 2000, p. 1029704, <https://doi.org/10.1117/12.375224>.
- [151] A. Mandal, D. Pal, V. Agrahari, H.M. Trinh, M. Joseph, A.K. Mitra, Ocular delivery of proteins and peptides: challenges and novel formulation approaches, *Adv. Drug Deliv. Rev.* 126 (2018) 67–95, <https://doi.org/10.1016/j.addr.2018.01.008>.
- [152] F.E. Pearson, C.L. McNeilly, M.L. Crichton, C.A. Primiero, S.R. Yukiko, G.J. P. Fernando, X. Chen, S.C. Gilbert, A.V.S. Hill, M.A.F. Kendall, Dry-coated live viral vector vaccines delivered by nanopatch microprojections retain long-term thermostability and induce transgene-specific T cell responses in mice, *PLoS One* 8 (2013), e67888, <https://doi.org/10.1371/journal.pone.0067888>.
- [153] S.G. Schwartz, H.W. Flynn Jr., T. Das, W.F. Mieler, Ocular infection: endophthalmitis, in: *Dev. Ophthalmol*, Karger Publishers, 2016, pp. 176–188, <https://doi.org/10.1159/000431195>.
- [154] H.-J. Jian, R.-S. Wu, T.-Y. Lin, Y.-J. Li, H.-J. Lin, S.G. Harroun, J.-Y. Lai, C.-C. Huang, Super-cationic carbon quantum dots synthesized from spermidine as an eye drop formulation for topical treatment of bacterial keratitis, *ACS Nano* 11 (2017) 6703–6716, <https://doi.org/10.1021/acsnano.7b01023>.
- [155] T.J. Duncan, K. Baba, Y. Oie, K. Nishida, A novel method using quantum dots for testing the barrier function of cultured epithelial cell sheets, *Investig. Ophthalmol. Vis. Sci.* 56 (2015) 2215, <https://doi.org/10.1167/iovs.14-15579>.